DRUG NAME: Hyoscine Hydrobromide (Scopolamine)

INN: Hyoscine
USAN: Scopolamine
Chemical nature: Naturally occurring tropane alkaloid; tertiary amine antimuscarinic agent.

⚠️ Critical distinction — do NOT confuse with hyoscine butylbromide:
Hyoscine hydrobromide (this monograph) is a tertiary amine that crosses the blood-brain barrier and exerts both central and peripheral antimuscarinic effects (antiemetic, sedative, amnestic, antisecretory). Hyoscine butylbromide (scopolamine butylbromide; brand: Buscopan) is a quaternary ammonium compound that does NOT cross the blood-brain barrier and acts only peripherally as a gastrointestinal/genitourinary antispasmodic. These two drugs have fundamentally different pharmacological profiles, indications, dosing, and adverse-effect profiles. Prescribing errors between the two have been documented and can result in unexpected CNS depression or inadequate antispasmodic effect.

Therapeutic Class:

Anticholinergic (Antimuscarinic)

Subclass:

Tertiary Amine Muscarinic Receptor Antagonist (Centrally-Acting)

Distinguishes this drug from quaternary ammonium antimuscarinics (glycopyrrolate, hyoscine butylbromide, ipratropium) that do not cross the blood-brain barrier. The centrally-acting property is responsible for the antiemetic, sedative, and amnestic effects unique to hyoscine hydrobromide.

Schedule (India):

Schedule H

All formulations (injectable, oral, transdermal, ophthalmic) are Schedule H drugs. A valid prescription is required for dispensing. No OTC status exists for any formulation of hyoscine hydrobromide in India.

Route(s):

IV (intravenous — bolus)
IM (intramuscular)
SC (subcutaneous)
Oral (tablets — swallowed whole)
Transdermal (adhesive patch — applied to postauricular skin behind the ear)
Ophthalmic (eye drops — specialist ophthalmology use for cycloplegia/mydriasis; limited availability in India)

ℹ️ The injectable route (IV/IM/SC) is the most commonly used route in Indian hospital practice (preanaesthetic medication, palliative care). Oral tablets and transdermal patches have limited retail availability in India.

Biosimilar Status:

Not a biologic — biosimilar classification not applicable. Hyoscine hydrobromide is a small-molecule chemical drug (tropane alkaloid) manufactured by chemical synthesis or extraction from plant sources (Datura or Duboisia species).

Formulations Available in India:

Single-ingredient formulations:

Dosage Form	Strengths Available	Notes
Injection (ampoule)	0.4 mg/1 mL; 0.6 mg/1 mL	Most widely available formulation in India. Used in premedication, palliative care, and emergency settings. Clear, colourless solution for IV, IM, or SC injection.
Tablets	0.3 mg	Limited availability in Indian retail pharmacies. Used primarily for motion sickness prophylaxis. Some brands may be imported. Verify local availability before prescribing.
Transdermal patch	1.5 mg patch (delivers approximately 1 mg of hyoscine over 72 hours)	Limited availability in India — primarily imported product (e.g., Transderm Scōp). Not consistently stocked in most Indian pharmacies. Applied to clean, dry, hairless postauricular skin. Self-adhesive matrix or reservoir-type system.
Eye drops	0.25% w/v	Very limited availability. Atropine (1%), homatropine (2%), cyclopentolate (1%), and tropicamide (0.5–1%) are preferred cycloplegic agents in Indian ophthalmology practice.

ℹ️ Practical note for Indian prescribers: The injection formulation is reliably available in Indian hospitals and through government supply channels. For outpatient motion sickness prophylaxis, confirm oral tablet or patch availability at the patient’s local pharmacy before prescribing. If unavailable, consider alternative antiemetics (e.g., promethazine, cinnarizine, meclizine) that are more widely stocked.

Fixed-dose combinations (FDCs):

No commonly prescribed, clinically relevant, CDSCO-approved FDCs of hyoscine hydrobromide are in widespread Indian clinical use.

ℹ️ Hyoscine butylbromide (not hydrobromide) is available in several FDCs with analgesics (e.g., with paracetamol, with dicyclomine). These are different drugs and must not be conflated with hyoscine hydrobromide.

Banned/withdrawn formulations: No specific formulation or FDC containing hyoscine hydrobromide has been identified in recent CDSCO ban notifications. Prescribers should verify against the latest CDSCO gazette notifications.

PHARMACOKINETICS

Primary pharmacokinetic parameters:

Parameter	Value
Bioavailability (oral)	Data limited; estimated to be moderate. The drug is well absorbed from the gastrointestinal tract but undergoes significant first-pass hepatic metabolism, reducing systemic availability. Some sources estimate oral bioavailability at approximately 20–30%.
Bioavailability (transdermal)	Absorbed through intact postauricular skin; bypasses first-pass metabolism. Steady-state plasma levels achieved approximately 6–8 hours after patch application. Bioavailability through transdermal route is more consistent than oral.
Bioavailability (parenteral)	IV: 100%; IM/SC: near-complete absorption from the injection site.
Tmax	Oral: approximately 0.5–1 hour. IM/SC: approximately 20–60 minutes. IV: immediate (peak effect within minutes). Transdermal: approximately 24 hours after application (due to controlled-release design).
Protein binding	Data limited; estimated approximately 50%.
Volume of distribution (Vd)	Data limited; estimated approximately 1.4 L/kg. The drug is lipophilic and distributes widely into tissues, including the central nervous system (crosses the blood-brain barrier — tertiary amine). Also crosses the placental barrier and enters breast milk.
Metabolism	Hepatic; primarily by conjugation reactions (glucuronidation, sulfation). Exact cytochrome P450 isoform involvement is not well characterised in the literature. Hyoscine hydrobromide is not a significant CYP450 inhibitor or inducer at therapeutic doses. No clinically significant drug transporter interactions (P-glycoprotein, OATP1B1/1B3, BCRP, OAT1/3, OCT2, MATE1/2) have been documented, though formal transporter interaction data is limited.
Active metabolites	No clinically significant active metabolites identified. The parent drug is responsible for pharmacological activity.
Half-life (t½)	Approximately 4–8 hours (variability across sources). Terminal half-life may be at the longer end of this range. Half-life may be prolonged in elderly patients and those with significant hepatic impairment.
Excretion	Primarily renal — excreted as conjugated metabolites with less than 10% of the dose eliminated as unchanged drug in the urine. Minor faecal excretion.
Dialysability	Data limited. Given the moderate-to-large volume of distribution (~1.4 L/kg) and approximately 50% protein binding, significant removal by haemodialysis is not expected. Formal dialysis clearance data for hyoscine hydrobromide is lacking.
Food effect	No clinically significant food effect documented for the oral formulation. Oral tablets may be taken with or without food.
Onset of action	IV: within 5–10 minutes (peak CNS effect within 20–60 minutes). IM/SC: 15–30 minutes. Oral: 30–60 minutes. Transdermal: 4–8 hours (initial onset); full steady-state effect at approximately 24 hours. Ophthalmic: mydriasis within 15–30 minutes; cycloplegia within 30–60 minutes.
Duration of action	IV: 2–4 hours (single dose). IM/SC/Oral: 4–6 hours (single dose). Transdermal: up to 72 hours per patch (effects may persist for up to 24 hours after patch removal due to skin depot). Ophthalmic: mydriasis may last 3–7 days; cycloplegia 1–3 days (shorter than atropine).

Special pharmacokinetic notes:

Transdermal delivery kinetics: The patch is designed for approximately zero-order release. After patch removal, a residual drug depot remains in the skin and continues to be absorbed for several hours. Patients should be warned that anticholinergic effects (dry mouth, blurred vision, drowsiness) may persist for up to 24 hours after patch removal.
Placental transfer: Hyoscine hydrobromide crosses the placental barrier. Fetal effects (tachycardia, reduced beat-to-beat heart rate variability) have been documented when administered to the mother.
Breast milk excretion: Small quantities are excreted into breast milk. The clinical significance for the nursing infant is uncertain but potential sedation and anticholinergic effects (reduced feeding, tachycardia, temperature dysregulation) should be monitored.
Ophthalmic route — systemic absorption: After topical ocular instillation, systemic absorption occurs through nasolacrimal drainage and conjunctival vasculature. Systemic anticholinergic side effects (dry mouth, tachycardia, flushing, drowsiness, CNS effects) are possible, particularly in children, the elderly, and individuals with low body weight. Punctal occlusion after instillation reduces systemic absorption.
Non-linear PK: No clinically significant non-linear pharmacokinetics, autoinduction, or saturation kinetics have been reported at therapeutic doses.

Population Pharmacokinetic Notes:

Population	PK Consideration
Elderly (≥60 years)	⚠️ Increased sensitivity to both central (confusion, delirium, sedation, hallucinations) and peripheral (urinary retention, constipation, tachycardia, xerostomia) anticholinergic effects. This is due to both pharmacokinetic factors (reduced hepatic clearance, reduced renal function) and pharmacodynamic factors (decreased central cholinergic reserve, increased blood-brain barrier permeability). Lower doses recommended.
Paediatric	Children, especially those under 6 years, may exhibit paradoxical excitatory responses (agitation, restlessness, hallucinations, seizures) instead of the expected sedation. Neonates and infants are particularly susceptible to anticholinergic toxicity due to immature hepatic conjugation pathways and incomplete blood-brain barrier maturation.
Pregnancy	Crosses placenta. No formal pregnancy PK studies. Theoretical risk of reduced placental blood flow due to maternal tachycardia.
Obesity	Data limited. Given the moderate Vd (~1.4 L/kg), dosing based on ideal body weight is generally appropriate for parenteral administration to avoid excessive dosing. Increased adipose tissue may prolong duration of effect from transdermal formulations.
Renal impairment	Less than 10% of the drug is excreted unchanged renally; however, conjugated metabolites may accumulate in severe renal impairment. Clinical significance is uncertain. Use with caution; monitor for excessive anticholinergic effects.
Hepatic impairment	Hepatic conjugation is the primary clearance pathway. Reduced clearance expected in moderate-to-severe hepatic impairment. Use lower doses and monitor for prolonged/excessive effects.
Critical illness / ICU	Data limited specifically for hyoscine hydrobromide. In critically ill patients, anticholinergic effects may be exaggerated and contribute to ICU delirium, ileus, and tachycardia. The altered volume of distribution in critical illness (fluid shifts, hypoalbuminaemia) may affect drug distribution. Use the lowest effective dose.

INDICATIONS + DOSING — FOR CLINICIAN USE ONLY

⛔ This section is a clinical reference for qualified prescribers only. Not for self-medication or patient self-dosing.

Primary Indications (Approved / Standard in India)

1. PREANAESTHETIC MEDICATION (Antisialagogue, Sedation, Amnesia, Vagolytic)

Clinical context: Hyoscine hydrobromide is used as premedication before general anaesthesia to reduce salivary, tracheobronchial, and pharyngeal secretions (antisialagogue effect), provide sedation and anterograde amnesia, reduce gastric acid volume, and provide a degree of vagolytic protection against bradycardia during intubation and surgical manipulation.

Multi-route dosing table — Adults:

Route	Starting Dose	Titration	Usual Maintenance Dose	Maximum Dose	Clinical Notes
IM (preferred for premedication)	0.2–0.4 mg as a single dose	Not applicable (single pre-procedural dose)	Not applicable	Max 0.6 mg per dose; single administration only	Administer 30–60 minutes before induction of anaesthesia. IM is the traditional premedication route.
SC	0.2–0.4 mg as a single dose	Not applicable	Not applicable	Max 0.6 mg per dose; single administration only	Administer 30–60 minutes before induction. Absorption may be slightly slower than IM; onset ~20–30 minutes.
IV	0.2–0.4 mg as a single dose	Not applicable	Not applicable	Max 0.4 mg per dose by IV bolus; single administration	Administer at induction or immediately before. Give slowly over 2–3 minutes to minimise transient tachycardia. IV route provides most rapid onset (within 5–10 minutes) and is preferred when rapid antisecretory/amnestic effect is needed.

ℹ️ Dose selection within range: The lower dose (0.2 mg) is generally adequate for antisialagogue effect alone. The higher dose (0.4–0.6 mg IM/SC, or 0.4 mg IV) provides more pronounced sedation and amnesia but increases the risk of tachycardia, xerostomia, and postoperative confusion.

Mandatory Clinical Notes:

When to prefer this drug over alternatives: Prefer hyoscine hydrobromide over atropine when amnesia and sedation are specifically desired as part of premedication (e.g., for awake fibreoptic intubation, uncomfortable procedures, patients with high anxiety). Prefer over glycopyrrolate when central sedation/amnesia is desired, as glycopyrrolate does not cross the blood-brain barrier. Prefer over atropine when tachycardia must be minimised — hyoscine causes less tachycardia than atropine at equivalent antisecretory doses.
When NOT to use even though technically indicated:
- ⚠️ Elderly patients at risk of postoperative delirium or cognitive dysfunction (POCD) — glycopyrrolate is strongly preferred in this population because it does not cross the BBB.
- Patients with uncontrolled narrow-angle glaucoma.
- Patients with bowel or urinary obstruction (anticholinergic effects worsen obstruction).
- Patients with known paradoxical reactions to anticholinergics.
- Patients with severe cardiac disease where any degree of tachycardia is dangerous (e.g., severe aortic stenosis, hypertrophic cardiomyopathy with outflow obstruction).
- ⚠️ If only antisialagogue effect is required (without sedation/amnesia), glycopyrrolate is preferred — equally effective peripherally, no CNS effects, more predictable heart rate effect.
NLEM India status: Hyoscine hydrobromide is NOT listed in NLEM India 2022 for preanaesthetic medication. Atropine sulphate injection and glycopyrrolate injection are listed. However, hyoscine hydrobromide injection is stocked in most Indian tertiary hospital pharmacies and is part of anaesthesiology practice nationwide.
Typical time to expected clinical response:
- IV: onset within 5–10 minutes; peak effect 20–60 minutes.
- IM/SC: onset 15–30 minutes; peak effect 30–60 minutes.
- Antisialagogue effect and sedation are the earliest observed effects.
Criteria for treatment failure and switching: If secretions remain excessive despite adequate dose, consider adding glycopyrrolate (0.2 mg IV) as a rescue antisialagogue rather than repeating hyoscine (to avoid cumulative CNS depression). If sedation is inadequate, consider a benzodiazepine (midazolam) rather than additional hyoscine.
Mandatory baseline investigations: No mandatory laboratory investigations before a single premedication dose. However:
- RECOMMENDED: Check baseline heart rate (hyoscine can cause transient bradycardia followed by tachycardia). Document baseline mental status in elderly patients.
- MANDATORY: Confirm no history of narrow-angle glaucoma (ask specifically).
- MANDATORY in males >50 years: Enquire about prostatism/urinary retention symptoms.
Specialist initiation: Preanaesthetic use is inherently specialist — administered by the anaesthesiologist or under anaesthesia team supervision. Not applicable for primary care prescribing.
Indian guideline source: Standard anaesthesiology practice in India; referenced in most Indian anaesthesiology textbooks (Aitkenhead, Smith & Aitkenhead adapted editions). No specific ICMR guideline exists. Practice is consistent with AIIMS anaesthesiology department protocols.
Key disease-specific safety warning: ⚠️ In patients with pre-existing tachycardia (heart rate >100 bpm), hyoscine can paradoxically cause a transient initial bradycardia (via low-dose vagal stimulation before muscarinic blockade predominates), followed by tachycardia. Monitor heart rate continuously peri-administration.
Common dose adjustment scenarios:
- Elderly (≥60 years): Use 0.1–0.2 mg maximum. Glycopyrrolate is strongly preferred.
- Low body weight (<50 kg): Use lower end of dose range (0.2 mg).
- Renal impairment: No formal adjustment required for a single dose, but monitor for prolonged effects.
- Hepatic impairment: Use lower dose (0.2 mg); monitor for prolonged sedation.
- Concomitant opioids/sedatives in premedication: Reduce hyoscine dose to 0.2 mg to avoid excessive sedation and respiratory depression.

2. MOTION SICKNESS — PROPHYLAXIS

Clinical context: Hyoscine hydrobromide is the most effective single agent for the prevention of motion sickness. It acts centrally on the vestibular nuclei and the vomiting centre in the medulla by blocking muscarinic (primarily M₁ and M₃) and histaminic pathways. It is most effective when given prophylactically before motion exposure rather than after symptoms develop.

Multi-route dosing table — Adults:

Route	Starting Dose	Titration	Usual Maintenance Dose	Maximum Dose	Clinical Notes
Oral (tablet)	0.3 mg as a single dose	Not applicable (dose repeated PRN)	0.3 mg every 6–8 hours as needed during travel	Max 0.3 mg per dose; Max 0.9 mg per day (some sources permit up to 1.2 mg/day; Indian product inserts generally recommend ≤0.9 mg/day)	Take 30 minutes before travel. Most effective when given before motion exposure begins.
Transdermal (patch)	Apply 1 patch (1.5 mg; delivers ~1 mg over 72 hours) to postauricular skin	Not applicable	1 patch every 72 hours for continued exposure	Max 1 patch at a time	Apply at least 4 hours before travel (ideally the evening before, i.e., 8–12 hours before exposure, for full efficacy). Replace every 72 hours if travel continues. Apply to clean, dry, hairless skin behind the ear. Wash hands thoroughly after handling patch to avoid inadvertent ocular contamination causing anisocoria.

ℹ️ Timing is critical: The drug must be given before the onset of motion sickness to be maximally effective. Once nausea and vomiting have begun, oral absorption is unreliable and the antiemetic effect of hyoscine is reduced. If the patient is already symptomatic, consider parenteral ondansetron or promethazine IM instead.

Mandatory Clinical Notes:

When to prefer this drug over alternatives: Hyoscine hydrobromide is the most effective single agent for motion sickness prophylaxis (superior to antihistamines like cinnarizine, dimenhydrinate, meclizine in comparative trials). Preferred for sea sickness and space-motion sickness where vestibular stimulation is severe. The transdermal patch is ideal for prolonged exposure (sea voyages, multi-day travel).
When NOT to use even though technically indicated:
- Elderly patients or those with prostatic hypertrophy, narrow-angle glaucoma, or cognitive impairment — prefer meclizine or cinnarizine.
- Patients who need to remain fully alert (drivers, pilots, operators of heavy machinery) — hyoscine causes significant drowsiness and impaired cognitive function. Meclizine or low-dose cinnarizine are less sedating alternatives.
- Children <10 years (high risk of paradoxical excitation; use age-appropriate alternatives — promethazine, dimenhydrinate in appropriate doses).
NLEM India status: Not listed in NLEM India 2022 for motion sickness.
Typical time to expected clinical response:
- Oral: 30–60 minutes.
- Transdermal: 4–8 hours (partial onset); full effect at approximately 24 hours. This is why the patch must be applied the evening before travel for optimal prophylaxis.
Criteria for treatment failure and switching: If motion sickness occurs despite properly timed hyoscine, consider adding a non-sedating antihistamine (e.g., meclizine 25 mg). Do not combine hyoscine with other anticholinergics (additive anticholinergic toxicity). For refractory cases requiring travel, consider onboard parenteral ondansetron.
Mandatory baseline investigations: None required for short-term prophylactic use. Clinical assessment for contraindications (glaucoma, prostatism, cardiac history) is sufficient.
Specialist initiation: Not required. May be prescribed by any registered medical practitioner. However, availability of the oral and transdermal formulations in India is limited; prescribers should confirm local availability.
Indian guideline source: No specific Indian guideline addresses motion sickness pharmacotherapy in detail. Practice is consistent with international consensus. API Textbook of Medicine (current edition) mentions hyoscine as the drug of choice for motion sickness prophylaxis. Goodman & Gilman (14th Edition, Chapter on Histamine, Serotonin, and the Ergot Alkaloids / Muscarinic Receptor Antagonists) provides the pharmacological basis.
Key disease-specific safety warning: ⚠️ Transdermal patch — withdrawal effect: Abrupt removal of the patch after prolonged use (>72 hours) can cause rebound nausea, vomiting, headache, and dizziness (cholinergic rebound). Advise gradual withdrawal (e.g., cut patch in half for the final day if available as non-reservoir type, or simply warn the patient about potential rebound symptoms and manage symptomatically).
Common dose adjustment scenarios:
- Elderly: Oral dose 0.15 mg (half tablet) every 8 hours. Transdermal patch: use half a patch if available (cut only non-reservoir matrix-type patches; do NOT cut reservoir-type patches). Alternatively, avoid hyoscine entirely and use meclizine 12.5–25 mg.
- Hepatic impairment: Reduce oral dose. Monitor for excessive sedation.
- Renal impairment: No specific adjustment for short-term use; monitor for excessive anticholinergic effects.

3. PREVENTION OF POSTOPERATIVE NAUSEA AND VOMITING (PONV)

Clinical context: Hyoscine hydrobromide reduces PONV through its central antiemetic action (vestibular nuclei, vomiting centre) and by reducing gastrointestinal secretions and motility. The transdermal patch is the best-studied formulation for this indication internationally. In Indian practice, the injectable formulation is more commonly used.

Multi-route dosing table — Adults:

Route	Starting Dose	Titration	Usual Maintenance Dose	Maximum Dose	Clinical Notes
Transdermal (patch)	Apply 1 patch (1.5 mg)	Not applicable	1 patch; remove 24 hours after surgery (or up to 72 hours if continued nausea risk)	Max 1 patch at a time	Apply the evening before surgery OR at least 4 hours before the end of anaesthesia (to allow therapeutic drug levels by emergence). Apply to dry, hairless postauricular skin.
IV	0.2–0.4 mg as a single dose	Not applicable	May repeat once after 6 hours if needed	Max 0.4 mg per dose; Max 0.8 mg per day (in divided doses)	Administer at the end of surgery, approximately 30 minutes before anticipated emergence. Give slowly over 2–3 minutes.
IM	0.2–0.4 mg as a single dose	Not applicable	May repeat once after 6 hours if needed	Max 0.6 mg per dose; Max 0.8 mg per day	Administer 30–60 minutes before anticipated end of surgery or in the PACU at first sign of nausea.

ℹ️ Multimodal PONV prophylaxis: Current anaesthesiology practice recommends a multimodal approach for patients at moderate-to-high risk of PONV (Apfel score ≥2). Hyoscine is typically used as part of a combination (e.g., with dexamethasone + ondansetron), not as a sole antiemetic. Its additive mechanism of action (anticholinergic/antihistaminic vs serotonergic) makes it a rational component of multimodal prophylaxis.

Mandatory Clinical Notes:

When to prefer over alternatives: Consider hyoscine as the third or fourth agent in multimodal PONV prophylaxis, especially in patients undergoing procedures with high PONV risk (laparoscopic surgery, gynaecological surgery, strabismus surgery, middle ear surgery). The transdermal patch is particularly useful for patients who will have continued nausea risk postoperatively (e.g., opioid PCA use, day-case surgery where oral antiemetics may not be tolerated). Preferred when ondansetron and dexamethasone have already been administered and additional prophylaxis is desired.
When NOT to use:
- Elderly patients at high risk of POCD or delirium — ondansetron, dexamethasone, and droperidol (low-dose) are preferred.
- Patients with pre-existing tachycardia, urinary retention risk (BPH), or narrow-angle glaucoma.
- ⚠️ If the patient already received atropine or glycopyrrolate as premedication — adding hyoscine increases total anticholinergic burden significantly. Reduce the hyoscine dose or omit.
NLEM India status: Not listed in NLEM India 2022 specifically for PONV. Ondansetron and dexamethasone are the NLEM-listed antiemetics used in PONV prophylaxis.
Typical time to expected clinical response: IV: antiemetic effect within 15–30 minutes. Transdermal: requires at least 4 hours for initial therapeutic levels.
Criteria for treatment failure: If PONV occurs despite hyoscine, add/switch to a different mechanistic class — ondansetron (5-HT₃ antagonist), dexamethasone, or low-dose droperidol. Do not repeat hyoscine if the first dose was ineffective.
Mandatory baseline investigations: No specific investigations required beyond standard preoperative assessment. Verify absence of contraindications (glaucoma, prostatism).
Specialist initiation: Administered by the anaesthesiology team. Not applicable for primary care.
Indian guideline source: Indian Society of Anaesthesiologists (ISA) practice is consistent with Society for Ambulatory Anesthesia (SAMBA) consensus guidelines, adapted for Indian drug availability. API Textbook does not specifically address PONV pharmacotherapy in detail; this is within anaesthesiology specialist domain.
Key safety warning: ⚠️ Postoperative visual disturbance: Transdermal patch can cause unilateral mydriasis (anisocoria) if the patient touches the patch and then rubs the eye. This can mimic a neurological emergency (third cranial nerve palsy, raised intracranial pressure) and may trigger unnecessary CT/MRI imaging. Educate nursing staff and patients to avoid touching the patch and to wash hands if they do. Document patch application in anaesthesia notes.
Common dose adjustment scenarios:
- Elderly: Reduce dose to 0.2 mg IV/IM. Avoid transdermal patch in patients >75 years or those with cognitive impairment. Glycopyrrolate + ondansetron is the preferred combination.
- Renal/hepatic impairment: No formal adjustment for single PONV prophylaxis dose; use lower end of range.

4. MYDRIASIS AND CYCLOPLEGIA (Ophthalmic Use)

Clinical context: Hyoscine hydrobromide 0.25% eye drops produce both mydriasis (pupil dilation) and cycloplegia (paralysis of accommodation) through muscarinic receptor blockade in the iris sphincter and ciliary muscle. In Indian ophthalmology practice, atropine (1%), homatropine (2%), cyclopentolate (1%), and tropicamide (0.5–1%) are more commonly used; hyoscine eye drops have very limited availability.

Dosing — Adults and Adolescents:

Parameter	Details
Formulation	Hyoscine hydrobromide 0.25% ophthalmic solution
For refraction (cycloplegic refraction)	Instil 1–2 drops into the conjunctival sac of each eye. Repeat after 5–10 minutes if needed. Perform refraction 45–60 minutes after the last instillation (once cycloplegia is complete).
For fundoscopy (mydriasis)	Instil 1 drop into each eye. Adequate mydriasis usually achieved within 20–30 minutes.
Maximum dose	2 drops per eye per session. Do not exceed without ophthalmologist supervision.
Duration of effect	Mydriasis: 3–7 days (prolonged). Cycloplegia: 1–3 days. Shorter duration than atropine but longer than tropicamide or cyclopentolate.

Mandatory Clinical Notes:

When to prefer over alternatives: Hyoscine hydrobromide has very limited clinical niche in Indian ophthalmology. Tropicamide (0.5–1%) is preferred for routine fundoscopy (shortest duration). Cyclopentolate (1%) is preferred for cycloplegic refraction in adults and older children (intermediate duration, adequate cycloplegia). Atropine (1%) is preferred for paediatric cycloplegic refraction (strongest cycloplegia, especially in heavily pigmented irides). Hyoscine may be considered when cyclopentolate is contraindicated (e.g., allergy) and atropine’s prolonged effect (7–14 days) is undesirable.
When NOT to use: ⛔ Narrow-angle glaucoma or anatomically narrow anterior chamber angle — risk of precipitating acute angle-closure crisis. ⛔ Known hypersensitivity to belladonna alkaloids.
NLEM India status: Not listed. Atropine eye drops and tropicamide eye drops are NLEM-listed.
Typical time to response: Mydriasis 15–30 minutes; cycloplegia 30–60 minutes.
Treatment failure criteria: If adequate mydriasis/cycloplegia is not achieved, switch to atropine 1% drops (with appropriate warnings about prolonged effect).
Baseline investigations: Slit-lamp assessment of anterior chamber depth to rule out narrow angle before instillation. Baseline IOP measurement if glaucoma is suspected. MANDATORY in patients >40 years or those with hypermetropia, family history of glaucoma.
Specialist initiation: Ophthalmologist or optometrist use only. Not for primary care prescribing.
Indian guideline source: Standard ophthalmology practice. Kanski’s Clinical Ophthalmology (used widely in Indian ophthalmology training); Parsons’ Diseases of the Eye (Indian edition).
Key safety warning: ⚠️ Systemic absorption via nasolacrimal duct: Especially dangerous in children and elderly. Instruct punctal occlusion (press on inner corner of eye for 2–3 minutes after instillation) to minimise systemic absorption. Monitor for systemic anticholinergic effects (flushing, tachycardia, dry mouth, confusion, urinary retention).
Dose adjustment: No dose adjustment needed for the topical route, but extra caution regarding systemic absorption in elderly (use punctal occlusion rigorously, observe for 30–60 minutes post-instillation).

Secondary Indications — Adults Only (Off-label)

1. TERMINAL RESPIRATORY SECRETIONS (“DEATH RATTLE”) IN PALLIATIVE CARE

OFF-LABEL but accepted standard practice in India

Clinical context: In the terminal phase of illness (typically the last 24–48 hours of life), patients frequently develop noisy, rattling respirations caused by accumulation of secretions in the pharynx and trachea that cannot be cleared by the obtunded patient. While this is often more distressing to the family than to the patient, pharmacological management with antisecretory agents is standard palliative care practice. Hyoscine hydrobromide is one of the most widely used agents for this purpose globally and in Indian palliative care.

Dosing — Adults (Palliative care):

Route	Starting Dose	Titration	Usual Maintenance Dose	Maximum Dose	Clinical Notes
SC (preferred in palliative care — avoids need for IV access)	0.2–0.4 mg as a single PRN dose	May repeat every 4–6 hours as needed based on secretion burden	0.4 mg every 4–6 hours PRN OR continuous SC infusion via syringe driver: 1.2–2.4 mg over 24 hours	Max 0.4 mg per dose (bolus); Max 2.4 mg per day (via infusion or divided boluses)	SC injection is given into the anterior chest wall, upper arm, or anterior thigh. For continuous infusion, use a portable syringe driver (Graseby or equivalent).
IV	0.2–0.4 mg as a single PRN dose	Repeat every 4–6 hours as needed	Continuous IV infusion: 1.2–2.4 mg over 24 hours	Max 0.4 mg per dose; Max 2.4 mg per day	IV route used when venous access is already established.

ℹ️ Key clinical consideration — early vs late administration: Antisecretory agents are most effective when given early, at the first sign of accumulating secretions. They reduce new secretion production but do not clear secretions already pooled. Gentle postural drainage and suctioning (if tolerated) may be needed for existing secretions.

Evidence basis: Multiple systematic reviews and palliative care guidelines support the use of anticholinergic agents for terminal secretions, though evidence for superiority of one agent over another (hyoscine hydrobromide vs glycopyrrolate vs hyoscine butylbromide) is limited. Level of evidence: Moderate (multiple RCTs exist, but outcomes are difficult to standardise; palliative care guideline consensus is strong).

Indian source: Indian Association of Palliative Care (IAPC) treatment guidelines; Kerala State Palliative Care Policy treatment protocols; AIIMS palliative care formulary — all list hyoscine hydrobromide as a first-line option for terminal secretions.

💡 Choosing between antisecretory agents for death rattle:

Hyoscine hydrobromide: Provides concurrent sedation (which may be desirable in the terminal phase for an agitated patient). More likely to cause confusion/delirium (problematic if patient is still conscious).
Glycopyrrolate: Does NOT cross BBB — no sedation, no delirium. Preferred if the patient is still alert and wishes to communicate, or if delirium is already present.
Hyoscine butylbromide: Peripheral only. Less effective for secretions originating from the respiratory tract (compared to upper airway/oropharyngeal pooling). Does not cause sedation.

2. SIALORRHOEA (EXCESSIVE DROOLING) IN NEUROLOGICAL CONDITIONS

OFF-LABEL

Clinical context: Sialorrhoea (drooling) occurs in conditions where salivary production is normal or increased but oral clearance is impaired — Parkinson’s disease, motor neurone disease (MND/ALS), cerebral palsy (adults), post-stroke bulbar dysfunction, and medication-induced sialorrhoea (e.g., clozapine). Hyoscine hydrobromide reduces salivary production via muscarinic receptor blockade.

Dosing — Adults:

Route	Starting Dose	Titration	Usual Maintenance Dose	Maximum Dose	Clinical Notes
Transdermal (patch) — preferred for chronic use if available	Apply 1 patch (1.5 mg) postauricularly every 72 hours	Assess response after 1 week of continuous use	1 patch every 72 hours	Max 1 patch at a time	Preferred route for chronic management as it provides steady-state drug delivery and avoids peaks/troughs. Limited availability in India.
Oral	0.3 mg once or twice daily	Increase to three times daily if tolerated and needed	0.3 mg two to three times daily	Max 0.3 mg per dose; Max 0.9 mg per day	Limited tablet availability in India.
SC	0.2 mg every 8 hours	Titrate based on effect and tolerability	0.2–0.4 mg every 6–8 hours	Max 0.4 mg per dose; Max 1.2 mg per day	Used in palliative care settings (MND) when oral route is unreliable.

Evidence basis: Level of evidence: Moderate (limited RCTs specifically for hyoscine hydrobromide; stronger evidence exists for glycopyrrolate in this indication; supported by specialist neurology and palliative care consensus).

Indian context: Glycopyrrolate (oral 1 mg tablets) is more commonly used in Indian neurology practice for sialorrhoea due to better availability and lack of CNS sedation. Botulinum toxin injection into salivary glands is used at tertiary centres. Hyoscine transdermal patch is an option primarily at specialist centres in metro cities where the patch can be sourced.

⚠️ Key warning for clozapine-induced sialorrhoea: Hyoscine hydrobromide should be used with extreme caution in patients on clozapine — the additive anticholinergic burden increases risk of constipation/ileus (a known serious adverse effect of clozapine), urinary retention, and delirium. Glycopyrrolate or sublingual atropine drops are generally preferred for clozapine-induced sialorrhoea.

3. NAUSEA AND VOMITING IN PALLIATIVE CARE (Non-PONV)

OFF-LABEL but accepted standard practice in India

Clinical context: In palliative care, hyoscine hydrobromide is used to manage nausea and vomiting that is primarily vestibular or movement-related in origin (e.g., nausea exacerbated by movement in bedbound patients, raised intracranial pressure with a vestibular component), or as part of an antisecretory/antiemetic combination in patients with malignant bowel obstruction (see indication 4 below).

Dosing — Adults (Palliative care):

Route	Dose	Maximum	Notes
SC	0.2–0.4 mg every 6–8 hours PRN, OR continuous SC infusion 0.6–1.2 mg/24 hours	Max 0.4 mg per dose; Max 1.2 mg per day (for antiemesis; higher doses used for combined antisecretory/antiemetic effect in bowel obstruction)	For movement-related nausea in bedbound patients. Often combined with other antiemetics (haloperidol, ondansetron) in a syringe driver.
Transdermal	1 patch every 72 hours	Max 1 patch at a time	Useful for chronic nausea with vestibular component. Limited availability.

Evidence basis: Level of evidence: Weak (largely expert consensus and palliative care practice guidelines; no high-quality RCTs comparing hyoscine specifically for palliative nausea vs other antiemetics).

Indian source: IAPC guidelines; palliative care training modules used in AIIMS, Tata Memorial Hospital, and Calicut Institute of Palliative Medicine.

4. INOPERABLE MALIGNANT BOWEL OBSTRUCTION — ANTISECRETORY MANAGEMENT (Palliative)

OFF-LABEL but accepted standard practice in India

Clinical context: In patients with advanced abdominal malignancy and inoperable bowel obstruction, the goals of management are reduction of secretions, vomiting, and colic without surgery. Hyoscine hydrobromide reduces gastrointestinal secretions and peristalsis, thereby reducing vomiting and colic. It is used as part of a three-drug combination (hyoscine hydrobromide + haloperidol/metoclopramide + octreotide ± dexamethasone) in many palliative care protocols.

Dosing — Adults (Palliative care):

Route	Dose	Maximum	Notes
SC continuous infusion	1.2–2.0 mg over 24 hours via syringe driver	Max 2.4 mg per day	Combined with haloperidol (2.5–5 mg/24 hours SC) and octreotide (0.3–0.6 mg/24 hours SC) in many palliative care protocols.
SC bolus	0.4 mg every 4–6 hours PRN	Max 2.4 mg per day	If syringe driver unavailable.

Evidence basis: Level of evidence: Moderate (supported by palliative care guidelines; RCT data is limited but multiple observational studies and systematic reviews support the combination approach). Octreotide has stronger evidence for volume reduction.

⚠️ Do NOT use metoclopramide in complete bowel obstruction (prokinetic action increases colic). Hyoscine hydrobromide’s antispasmodic action is specifically advantageous here.

Indian source: IAPC malignant bowel obstruction protocol; Tata Memorial Hospital palliative care guidelines.

5. ADJUNCTIVE SEDATION FOR PROCEDURAL / DIAGNOSTIC PROCEDURES

OFF-LABEL

Clinical context: Hyoscine hydrobromide’s amnestic and sedative properties make it a useful adjunct for minor procedures (e.g., upper GI endoscopy in anxious patients — where conscious sedation with benzodiazepines alone is insufficient, MRI in claustrophobic patients — as an alternative to benzodiazepines). This is an uncommon off-label use.

Dosing — Adults:

Route	Dose	Maximum	Notes
IV	0.2–0.3 mg as a single dose, 15–30 minutes before procedure	Max 0.4 mg	Used in combination with a benzodiazepine (e.g., midazolam 1–2 mg IV). Monitor SpO₂ and vital signs. Resuscitation equipment must be available.
IM	0.2–0.4 mg as a single dose, 30–60 minutes before procedure	Max 0.4 mg	Alternative when IV access is not established before the procedure.

Evidence basis: Level of evidence: Weak (case series, expert opinion, and extrapolation from preanaesthetic use). Midazolam alone is usually sufficient; hyoscine is added only in selected cases.

PAEDIATRIC DOSING (Specialist Only)

⛔ All paediatric use of hyoscine hydrobromide must be under specialist supervision (anaesthesiologist, paediatrician, or palliative care specialist). Not for unsupervised primary care prescribing in children.

General Notes:

⚠️ Paradoxical excitation: Children, especially those under 6 years, are at significant risk of paradoxical CNS excitation (agitation, hyperactivity, restlessness, hallucinations, seizures) rather than the expected sedation seen in adults. This risk is highest in febrile children and those receiving concurrent CNS-active drugs.
⚠️ Anticholinergic toxicity: Neonates and infants have immature hepatic conjugation pathways, incomplete blood-brain barrier maturation, and higher sensitivity to anticholinergic effects. Temperature dysregulation (hyperthermia due to suppressed sweating) is a particular concern in the hot Indian climate.
Safety monitoring requirements:
- Continuous heart rate and SpO₂ monitoring during and for at least 30–60 minutes after parenteral administration.
- Monitor temperature (risk of hyperthermia from suppressed sweating — especially relevant in Indian climate).
- Monitor for urinary retention (especially postoperatively).
- Monitor mental status and level of consciousness.
- Monitor bowel sounds (risk of ileus, especially when combined with opioids).
Minimum age: Generally avoided in children <3 months (some references state <6 months). Use in neonates (<28 days) is exceptional and restricted to NICU settings.
Minimum weight: No strict minimum weight threshold defined; however, extreme caution is warranted in infants <5 kg due to enhanced susceptibility to toxicity and difficulty in accurate dose measurement.
Formulation suitability for children:
- Injectable (0.4 mg/mL or 0.6 mg/mL): Suitable — allows accurate weight-based dose calculation. Requires dilution for very small doses in neonates/infants to ensure accurate measurement.
- Oral tablet (0.3 mg): NOT practically suitable for young children — tablets cannot be easily split into the small doses required. No paediatric oral liquid formulation is commercially available in India. Extemporaneous preparation may be considered at specialist centres but stability data is limited.
- Transdermal patch (1.5 mg): ⛔ NOT recommended in children <12 years. The patch delivers a fixed dose that cannot be adjusted for body weight. Cutting the patch is unreliable for dose accuracy (and dangerous for reservoir-type patches). Risk of accidental transfer to child’s eyes (causing mydriasis) or mouth (causing systemic toxicity) is high.
- Eye drops (0.25%): May be used in children under ophthalmologist supervision, but cyclopentolate (1%) and atropine (1%) are preferred in Indian paediatric ophthalmology practice.
Palatability: Not applicable (no oral liquid formulation available; injectable is the primary paediatric route).

Dosing method: Weight-based (mg/kg) — preferred for all parenteral and oral dosing.

Adolescent transition: Children ≥12 years AND ≥40 kg may use adult dosing (refer to adult indications section). For adolescents 12–18 years weighing <40 kg, continue weight-based dosing.

Neonatal Dosing (<28 days of life)

⛔ Neonatal use — NICU supervision only

Hyoscine hydrobromide use in neonates is exceptional and not part of standard neonatal practice. Neonates are extremely sensitive to anticholinergic effects:

Immature hepatic conjugation → prolonged drug effect
Immature thermoregulatory mechanisms → high risk of hyperthermia
Immature blood-brain barrier → exaggerated CNS effects
Neonatal tachycardia response may mask cardiovascular compromise

Indication	Dose	Maximum	Notes
Preanaesthetic medication (neonatal surgery)	10–15 mcg/kg (0.01–0.015 mg/kg) IV or IM as a single dose	Max 15 mcg/kg per dose	Rarely used; glycopyrrolate (5 mcg/kg IV) or atropine (10–20 mcg/kg IV) are strongly preferred for neonatal premedication. Use only if specifically indicated by the neonatal anaesthesiologist.
Bradycardia during intubation	Not recommended. Atropine (20 mcg/kg IV) is the standard drug for neonatal intubation-associated bradycardia.	—	Hyoscine’s CNS effects are undesirable in neonates.

ℹ️ Dilution for neonatal use: The standard 0.4 mg/mL injection must be diluted to allow accurate measurement of small volumes. Dilute 0.4 mg (1 mL) in 9 mL of 0.9% sodium chloride to produce a 0.04 mg/mL (40 mcg/mL) solution. Use a 1 mL syringe for accurate measurement. Label clearly. Use immediately after dilution. Discard unused portion.

Primary Indications — Paediatric (Approved / Standard in India)

1. PREANAESTHETIC MEDICATION — Paediatric

Clinical context: Used in children to reduce secretions (antisialagogue), provide sedation, and reduce the risk of vagal-mediated bradycardia during intubation and surgical manipulation. In Indian paediatric anaesthesiology, atropine and glycopyrrolate are more commonly used; hyoscine hydrobromide is reserved for situations where concurrent sedation/amnesia is specifically desired.

Weight-based dosing table — Paediatric (≥3 months to <12 years):

Weight Range	Route	Dose	Maximum Absolute Dose	Notes
5–10 kg (approx. 3–12 months)	IM or SC	10 mcg/kg (0.01 mg/kg) as a single dose	Max 0.15 mg per dose	Administer 30–45 minutes before induction. Use 40 mcg/mL diluted solution for accurate measurement.
10–15 kg (approx. 1–3 years)	IM or SC	10–15 mcg/kg (0.01–0.015 mg/kg) as a single dose	Max 0.2 mg per dose	⚠️ Highest risk age group for paradoxical excitation. Consider glycopyrrolate instead.
15–20 kg (approx. 3–6 years)	IM or SC	10–15 mcg/kg as a single dose	Max 0.3 mg per dose	Monitor for paradoxical excitation.
20–30 kg (approx. 6–10 years)	IM or SC	10–15 mcg/kg as a single dose	Max 0.3 mg per dose	Lower risk of paradoxical excitation in this age group.
30–40 kg (approx. 10–12 years)	IM or SC	10–15 mcg/kg as a single dose	Max 0.4 mg per dose	Approaching adult dosing range.
≥40 kg or ≥12 years	IM or SC	Use adult dosing (0.2–0.4 mg as a single dose)	Max 0.6 mg per dose (IM/SC); Max 0.4 mg per dose (IV)	Adult ceiling applies.

IV dosing (all paediatric ages ≥3 months):

6–10 mcg/kg (0.006–0.01 mg/kg) as a single IV dose, administered slowly over 2–3 minutes.
Max 0.3 mg per dose (IV) in children <30 kg.
Max 0.4 mg per dose (IV) in children ≥30 kg or ≥12 years.

Mandatory Clinical Notes (Paediatric-specific):

When to prefer over alternatives: Only when sedation and amnesia are specifically desired as part of premedication (e.g., difficult paediatric airway management with awake technique, extremely anxious child where midazolam alone is insufficient). For routine antisialagogue premedication in children, glycopyrrolate (5–10 mcg/kg IV/IM) is preferred (no CNS effects, no paradoxical excitation risk).
When NOT to use:
- ⚠️ Children with Down syndrome — increased sensitivity to anticholinergic effects, increased risk of paradoxical excitation, and increased risk of hyperthermia.
- Children with febrile illness — anticholinergic suppression of sweating combined with fever increases hyperthermia risk, especially in Indian summer conditions.
- Children with gastro-oesophageal reflux — reduces lower oesophageal sphincter tone, worsening reflux.
- Children with uncontrolled seizure disorders — may lower seizure threshold.
NLEM India status: Not listed. Atropine injection is the NLEM-listed anticholinergic premedication for children.
Time to response: IV: 5–10 minutes; IM/SC: 15–30 minutes.
Treatment failure: If secretions remain problematic, add glycopyrrolate rather than repeating hyoscine.
Mandatory baseline: Heart rate, temperature, document absence of glaucoma/prostatism (in adolescent males).
Specialist initiation: Mandatory — paediatric anaesthesiologist only.
Indian guideline source: IAP Textbook of Pediatrics (current edition) references hyoscine hydrobromide under anticholinergic premedication; standard Indian paediatric anaesthesiology teaching.
Key safety warning: ⚠️ Temperature monitoring is MANDATORY in all children receiving hyoscine hydrobromide, especially in non-air-conditioned OTs and recovery areas (common in district hospitals in India). Hyperthermia from impaired sweating can develop rapidly.
Dose adjustment: Reduce dose by 25–50% in children with hepatic impairment, concurrent CNS depressant use, or dehydration.

2. MOTION SICKNESS PROPHYLAXIS — Paediatric

Clinical context: Hyoscine hydrobromide is effective for motion sickness prevention in older children, but its use in young children is limited by the risk of paradoxical excitation, lack of appropriate paediatric oral formulations in India, and availability of safer alternatives (promethazine syrup, dimenhydrinate).

Dosing — Children ≥10 years:

Route	Dose	Maximum	Notes
Oral	0.3 mg (one tablet) as a single dose, 30 minutes before travel. May repeat every 6–8 hours if travel continues.	Max 0.3 mg per dose; Max 0.9 mg per day	Oral tablet availability in India is limited. Confirm availability before prescribing.
Transdermal (patch)	1 patch (1.5 mg) applied postauricularly at least 4 hours before travel; ideally the evening before. Replace every 72 hours.	Max 1 patch at a time	Only in children ≥12 years. Not recommended <12 years (fixed dose cannot be weight-adjusted). ⚠️ Limited availability in India.

Children 6–10 years:

Oral: 0.15 mg (half tablet) 30 minutes before travel. May repeat every 6–8 hours. Max 0.15 mg per dose; Max 0.45 mg per day. Accurate half-tablet dosing is difficult with 0.3 mg tablets; consider alternative agents.
Transdermal: ⛔ NOT recommended in children <12 years.
ℹ️ Preferred alternatives for children 6–10 years in Indian practice: Promethazine (0.25–0.5 mg/kg oral, available as syrup); dimenhydrinate (1–1.5 mg/kg oral, available as tablets and syrup); cinnarizine (available as tablets — not widely used in young children); meclizine (available as tablets — limited paediatric data).

Children <6 years:

⛔ Hyoscine hydrobromide is NOT recommended for motion sickness prophylaxis in children under 6 years due to high risk of paradoxical excitation, no appropriate formulation, and availability of safer alternatives.
Preferred alternatives: Promethazine syrup (>2 years), dimenhydrinate (>2 years), or non-pharmacological measures (positioning, visual fixation, ginger, acupressure wristbands).

Mandatory Clinical Notes (Paediatric-specific):

Prefer alternatives: In Indian practice, promethazine syrup is more readily available and easier to dose accurately in children than hyoscine hydrobromide tablets.
Warn caregivers: Drowsiness is expected. Do not allow the child to engage in activities requiring alertness (cycling, swimming) while medicated.
NLEM status: Not listed.
Specialist initiation: Not mandatory for children ≥10 years; however, for children 6–10 years, prescribing by a paediatrician is recommended.
Indian source: IAP guidelines on supportive care reference motion sickness briefly; no specific Indian paediatric motion sickness guideline exists.

3. MYDRIASIS AND CYCLOPLEGIA — Paediatric (Ophthalmic)

Dosing — Children:

Age Group	Formulation	Dose	Notes
>3 years	Hyoscine hydrobromide 0.25% eye drops	1 drop in each eye; repeat after 5–10 minutes if needed. Perform refraction after 45–60 minutes.	Very limited availability in India. Cyclopentolate 1% (≥1 year) or atropine 1% (all ages) are preferred in Indian paediatric ophthalmology.
<3 years	Not recommended	—	Use atropine 0.5% (for children <1 year) or atropine 1% (for 1–3 years) for cycloplegic refraction. Cyclopentolate 0.5–1% is an alternative ≥1 year.

⚠️ Systemic absorption risk is HIGHER in children than in adults due to lower body weight and proportionally larger nasolacrimal absorption surface. Punctal occlusion for 2–3 minutes after instillation is MANDATORY in all children. Observe the child for at least 30 minutes for signs of systemic anticholinergic toxicity: facial flushing, tachycardia, fever, agitation, hallucinations.

ℹ️ Practical note: In Indian paediatric ophthalmology practice, this drug is almost never used. Atropine eye drops (0.5–1%) remain the gold standard for cycloplegic refraction in children, especially in children with dark irides (common in the Indian population) where stronger cycloplegia is needed. Cyclopentolate 1% is the standard for routine refraction in children >1 year when shorter duration of effect is desired.

Secondary Indications — Paediatric (Off-label)

1. SIALORRHOEA IN PAEDIATRIC NEUROLOGICAL CONDITIONS (Cerebral Palsy, Neurodegenerative Conditions)

OFF-LABEL

Clinical context: Drooling is a significant problem in children with cerebral palsy (CP), severe neurological impairment, and neurodegenerative conditions. It causes skin maceration, social stigma, aspiration risk, and caregiver burden. Hyoscine hydrobromide (transdermal or oral) has been used to reduce salivary production.

Dosing — Children ≥3 years:

Route	Dose	Maximum	Notes
Transdermal (patch) — children ≥12 years and ≥30 kg	1 patch (1.5 mg) postauricularly every 72 hours	Max 1 patch at a time	⚠️ Limited availability in India. Monitor for CNS side effects (drowsiness, confusion), dry mouth (may impair swallowing paradoxically), urinary retention, and constipation.
Transdermal — children 6–12 years	Some centres use a quarter to half patch (cut only matrix-type patches; ⛔ never cut reservoir-type). Start with quarter patch.	Max half patch at a time	⚠️ Off-label dose reduction method. Dose accuracy is approximate. Close monitoring required.
Oral — children ≥6 years	0.1–0.15 mg every 8 hours (requires extemporaneous preparation from tablets — no commercial paediatric liquid available in India)	Max 0.3 mg per dose; Max 0.9 mg per day	Extemporaneous preparation stability is not well established.

Evidence basis: Level of evidence: Moderate (paediatric RCTs exist for transdermal scopolamine in CP-related sialorrhoea, predominantly non-Indian studies; supported by IAP rehabilitation committee recommendations and international CP management guidelines).

Preferred alternatives in Indian practice:

Glycopyrrolate oral solution (1 mg/5 mL — limited availability in India; tablets may be crushed and given via NG tube in some centres): Better evidence in paediatric sialorrhoea, no CNS effects. Dose: 40–100 mcg/kg/dose, three times daily. Max 3 mg/day.
Botulinum toxin injection into salivary glands: Available at tertiary centres; provides 3–6 months of effect; requires specialist (paediatric neurologist or ENT).
Trihexyphenidyl (benzhexol): Sometimes used in children with dystonic CP but has significant CNS side effects.

⚠️ Key warning: In neurologically impaired children who have difficulty swallowing, anticholinergic-induced thickening of remaining secretions may paradoxically worsen swallowing difficulty and increase aspiration risk. Monitor carefully.

2. TERMINAL SECRETIONS IN PAEDIATRIC PALLIATIVE CARE

OFF-LABEL but accepted standard practice

Dosing — Children ≥1 month:

Weight Range	Route	Dose	Maximum	Notes
<20 kg	SC or IV	10 mcg/kg every 4–6 hours PRN, OR continuous SC infusion 40–60 mcg/kg/24 hours	Max 0.3 mg per dose; Max 1.2 mg per day	Use diluted solution for accurate measurement.
20–40 kg	SC or IV	10–15 mcg/kg every 4–6 hours PRN, OR continuous SC infusion 40–80 mcg/kg/24 hours	Max 0.4 mg per dose; Max 2.0 mg per day	Approaching adult dosing at upper weight range.
≥40 kg	SC or IV	Use adult dosing	Max adult dose	See adult palliative care dosing section.

Evidence basis: Level of evidence: Weak (extrapolated from adult palliative care practice; limited paediatric-specific data; supported by paediatric palliative care consensus guidelines including Together for Short Lives [UK] and Indian paediatric palliative care modules).

Indian source: MoHFW Essential Package for Paediatric Palliative Care; Pallium India training modules.

ℹ️ If glycopyrrolate is available, it is preferred in children who are still conscious, as it avoids CNS sedation and paradoxical excitation.

MISSED DOSE / DELAYED DOSE GUIDANCE

Context-specific guidance by route and clinical use:

1. PRN / Acute / Single-Dose Use (premedication, procedural sedation, acute PONV):

Not applicable — these are single-dose or as-needed administrations. There is no scheduled dosing to “miss.”

2. Oral Tablets for Motion Sickness (PRN use during travel):

Not applicable — taken on an as-needed basis before travel. If a dose is missed during continued travel:

Take the missed dose as soon as remembered, unless the next scheduled dose is within 3 hours.
If within 3 hours of the next dose, skip the missed dose and take the next dose at the scheduled time.
⛔ Never take a double dose to compensate for a missed dose.

3. Transdermal Patch (motion sickness prophylaxis or sialorrhoea):

Scenario	Guidance
Patch falls off or is removed early	Apply a new patch to a different postauricular site (alternate ears). If <24 hours into the patch life, the new patch provides a full 72-hour cycle from the time of application. Note that onset of full effect will take 4–8 hours.
Forgotten to replace patch at 72 hours	Apply a new patch as soon as remembered. There is no need to “catch up” — the new patch provides its own 72-hour dosing cycle. Expect a gap in drug effect during the unpatched period (secretions or nausea may return).
Prolonged non-adherence (patch not replaced for >1 week after stopping)	Restart by applying a fresh patch. No re-titration needed. However, be aware that rebound cholinergic effects (nausea, vomiting, dizziness, headache) may have occurred during the gap period, especially if the patch was used continuously for >72 hours before stopping. These symptoms are self-limiting (24–72 hours).

⚠️ Rebound / withdrawal after prolonged patch use: Abrupt cessation of the transdermal patch after prolonged use (>3 days of continuous use) can cause a cholinergic rebound syndrome: nausea, vomiting, headache, dizziness, disequilibrium, and muscle weakness. This typically resolves within 24–72 hours. Counsel patients (or caregivers, for sialorrhoea patients) about this possibility.

4. Scheduled SC/IV Dosing in Palliative Care (e.g., for terminal secretions):

Scenario	Guidance
Bolus dosing: dose delayed by <2 hours	Give the dose as soon as remembered and resume the regular schedule.
Bolus dosing: dose delayed by >2 hours	Give the dose and adjust the schedule so subsequent doses are spaced every 4–6 hours from the given dose.
Continuous SC infusion interrupted	Restart the infusion as soon as possible at the same rate. If the interruption was >4 hours, secretions may have re-accumulated; a single SC bolus of 0.2–0.4 mg may be given to re-establish effect while restarting the infusion.
Multiple consecutive missed bolus doses (>2 missed)	Resume at the same dose. No re-titration needed (no risk of rebound from missing a few doses of an anticholinergic in this context). However, secretions will have accumulated; gentle suctioning and patient positioning may be needed while drug effect is re-established.

5. Prolonged Non-Adherence / Drug Holiday Guidance:

Hyoscine hydrobromide does not have significant rebound effects upon resumption of dosing (unlike beta-blockers, clonidine, or corticosteroids). The main concern with interruption is return of the symptoms being treated (secretions, nausea, drooling). There is:

No risk of immunogenicity (not a biologic).
No withdrawal syndrome from the drug itself upon stopping (the cholinergic rebound described above after prolonged transdermal use is a rebound of the blocked system, not a drug withdrawal syndrome per se).
No need for re-titration when resuming after interruption.

RECONSTITUTION / ADMINISTRATION QUICK REFERENCE (For Nurses & Clinical Staff)

Reconstitution:

Parameter	Details
Supplied as	Hyoscine hydrobromide injection 0.4 mg/mL or 0.6 mg/mL in 1 mL glass ampoules. Clear, colourless to faintly yellow solution. Ready-to-use — no reconstitution required.
Diluent for further dilution (if needed)	Compatible: 0.9% Sodium Chloride (Normal Saline) and 5% Dextrose (D5W).
Incompatible diluents	Alkaline solutions (e.g., sodium bicarbonate injection) — hyoscine may be hydrolysed in alkaline pH.
Dilution for neonatal/infant use	Dilute 0.4 mg (1 mL) in 9 mL of 0.9% NaCl to produce a 0.04 mg/mL (40 mcg/mL) solution. Use a 1 mL syringe for dose measurement. Label clearly with drug name and concentration. Use immediately; discard unused portion.

Rate of Administration:

Route	Administration Guidance
IV bolus/push	Administer slowly over 2–3 minutes. Rapid IV push may cause transient paradoxical bradycardia (before tachycardia), arrhythmias, or a sudden drop in blood pressure.
IV infusion (palliative care)	Dilute total 24-hour dose in 20–50 mL of 0.9% NaCl. Infuse at a constant rate via syringe pump or syringe driver over 24 hours. Example: 1.2 mg in 24 mL NaCl → run at 1 mL/hour.
IM injection	Inject deep into a large muscle mass (deltoid in adults and older children; anterolateral thigh [vastus lateralis] in infants and young children). Standard IM injection technique. Usual volume ≤1 mL.
SC injection	Inject into subcutaneous tissue of the anterior chest wall, upper arm, anterior thigh, or abdomen. Rotate sites if giving repeated doses. SC is the preferred route in palliative care (avoids need for IV access; generally well tolerated).
SC continuous infusion (syringe driver)	Use a portable syringe driver (e.g., Graseby MS26 or equivalent). Load the syringe with the required 24-hour dose diluted in an appropriate volume of 0.9% NaCl or Water for Injection (typically 10–20 mL for a 24-hour infusion via standard 20 mL syringe). Insert a 25G or 27G butterfly needle subcutaneously. Secure with transparent dressing. Change insertion site every 72 hours or sooner if site becomes inflamed.

Weight-Based Dosing Calculation Example (Paediatric Premedication — IM):

Example: A 15 kg child requires hyoscine hydrobromide 10 mcg/kg IM for premedication.

- Required dose = 15 × 10 = 150 mcg = 0.15 mg
- Using the standard 0.4 mg/mL ampoule:
  - Volume to draw = 0.15 / 0.4 = 0.375 mL
- Alternatively, using the diluted 0.04 mg/mL solution (for smaller children):
  - Volume to draw = 0.15 / 0.04 = 3.75 mL — easier to measure accurately.
- Administer as a deep IM injection into the vastus lateralis.

Syringe Driver Compatibility (Palliative Care):

Hyoscine hydrobromide is frequently combined with other drugs in a syringe driver for palliative care. Known compatibilities and incompatibilities:

Compatible in Same Syringe Driver	Incompatible — Use Separate Lines
Morphine sulphate	Cyclizine (may precipitate at higher concentrations — check local compatibility data)
Diamorphine (where available)	Dexamethasone (may precipitate — use a separate syringe)
Haloperidol	Diclofenac sodium
Midazolam	Phenobarbital (alkaline solution — precipitation risk)
Metoclopramide (at standard concentrations)	Ketorolac
Octreotide	—
Levomepromazine	—

⚠️ Always perform a visual compatibility check after mixing in the syringe. If cloudiness, colour change, or precipitation is observed, do NOT administer. Prepare drugs in separate syringes with separate infusion sites.

ℹ️ Practical Indian context note: Graseby-type syringe drivers may not be available in all palliative care settings in India. In resource-limited settings, intermittent SC bolus dosing every 4–6 hours is an acceptable alternative to continuous infusion.

Stability After Reconstitution/Dilution:

Condition	Stability
Undiluted ampoule (unopened)	Store at room temperature (below 30°C). Protect from light. Shelf life as per manufacturer (usually 2–3 years from manufacture).
After opening ampoule (undiluted)	Use immediately. Single-use ampoule — discard any unused portion. No preservative.
Diluted in 0.9% NaCl (for IV infusion or syringe driver)	Stable for 24 hours at room temperature (25°C). Use within 24 hours. Prepare fresh solution daily for continuous infusions.
Diluted in 0.9% NaCl (40 mcg/mL solution for paediatric use)	Use immediately. No stability data for this dilution. Discard unused portion.

Multi-Dose Vial Handling:

Not applicable — hyoscine hydrobromide injection is supplied in single-use glass ampoules in India. No multi-dose vials are available.

Y-site / Line Compatibility:

Data limited for hyoscine hydrobromide specifically. When administering IV, flush the line with 0.9% NaCl before and after administration to minimise compatibility concerns.

Special Administration Notes:

Parameter	Details
Filter requirements	No specific in-line filter required for IV administration.
Flush line	Flush IV line with at least 5 mL of 0.9% NaCl before and after IV bolus administration.
Extravasation risk	Low. Not a vesicant. SC administration is routine. In the unlikely event of perivenous leakage, observe for local irritation; no specific antidote needed.
IM injection site	Adults: deltoid muscle (for small volumes ≤1 mL). Children: anterolateral thigh (vastus lateralis). Avoid gluteal site in children <3 years.
Oral tablet	Swallow whole with water. Do not crush or chew (though no specific modified-release formulation exists; crushing is not recommended due to bitter taste).
Transdermal patch	Apply to clean, dry, hairless skin behind the ear (postauricular area). Do not cut reservoir-type patches. Press firmly for 10–15 seconds. Wash hands thoroughly after handling. Remove old patch before applying new one. If patch edges lift, apply a small strip of hypoallergenic medical tape to hold in place (do not apply a second patch over the first). After removal, fold patch in half (adhesive side inward) and discard safely — residual drug in the patch can be harmful if ingested by children or pets.
Eye drops	Instil into the lower conjunctival sac. Apply punctal occlusion (press on the inner corner of the eye near the nose) for 2–3 minutes immediately after instillation to reduce systemic absorption. Wipe away excess drops from the cheek.
Enteral tube (NG/NJ tube)	No commercial liquid formulation available. Tablets may theoretically be crushed and dispersed in 10 mL of water for NG administration, but this is not standard practice and stability/bioavailability through NG route is not well established. For patients requiring enteral anticholinergic antisecretory therapy, consider glycopyrrolate injection given via the parenteral route.

Cold-Chain Drug Guidance:

Not applicable — hyoscine hydrobromide injection is stored at room temperature (below 30°C), protected from light. No cold-chain requirement.

ℹ️ Indian climate note: Store below 30°C. In areas of India where ambient temperatures regularly exceed 30°C (much of the country from March to October), store in the coolest available area (not in direct sunlight, not in vehicles). Short-term exposure to temperatures up to 40°C during transport is unlikely to significantly degrade the drug, but prolonged storage above 30°C may reduce shelf life. There is no need for refrigeration unless specifically stated on the manufacturer’s label.

Storage Summary:

Condition	Storage
Injection (unopened)	Room temperature, below 30°C, protected from light.
Transdermal patch (sealed pouch)	Room temperature, below 25°C. Keep in sealed pouch until use.
Oral tablets	Room temperature, below 30°C, protected from moisture.
Eye drops	Room temperature, below 25°C. After opening, use within 28 days (as per manufacturer).

RENAL ADJUSTMENT

eGFR formula: The limited renal dosing guidance available for hyoscine hydrobromide does not specify which renal function estimate to use. Less than 10% of the drug is excreted unchanged in the urine; the primary elimination pathway is hepatic conjugation followed by renal excretion of metabolites. Therefore, renal impairment has a modest effect on overall drug clearance.

ℹ️ Overall: No formal dosing adjustment guidelines exist from CDSCO or standard pharmacological references. The following guidance is based on pharmacokinetic principles and clinical caution.

eGFR (mL/min)	Dose Adjustment	Notes
>60	No adjustment required.	Standard dosing applies.
30–60	No formal adjustment required. Use standard doses with monitoring.	Monitor for excessive anticholinergic effects (dry mouth, constipation, urinary retention, tachycardia, confusion in elderly). Conjugated metabolites may accumulate; clinical significance uncertain.
15–30	Use lower end of dose range.	Administer the minimum effective dose. Monitor closely for CNS effects (sedation, confusion) and peripheral anticholinergic effects. Increase dosing interval if used regularly (e.g., every 8 hours instead of every 6 hours).
<15 (non-dialysis)	Use with caution. Reduce dose by 25–50%.	⚠️ Enhanced risk of anticholinergic side effects due to metabolite accumulation and the increased sensitivity of uraemic patients to CNS-active drugs. Avoid if alternatives exist (glycopyrrolate — also requires caution in severe renal impairment but may be better tolerated peripherally).
Haemodialysis	Data limited. Significant removal by HD is not expected (moderate Vd, ~50% protein binding).	No supplemental post-dialysis dose is routinely required. If the drug is being used for terminal secretions or PONV in a dialysis patient, standard dosing with careful clinical monitoring is acceptable.
Peritoneal dialysis	Data limited. Not expected to be significantly removed.	Standard dosing with monitoring. Peritoneal dialysis patients may have altered fluid distribution affecting Vd.
CRRT	Data limited.	Use standard dosing; monitor for excessive anticholinergic effects. No formal CRRT dosing adjustment published.

Augmented Renal Clearance (ARC): Not clinically relevant for hyoscine hydrobromide, as renal clearance of unchanged drug is minimal (<10%). No dose increase required in ARC states.

HEPATIC ADJUSTMENT

Primary clearance pathway: Hepatic conjugation (glucuronidation, sulfation) is the major route of drug elimination. Significant hepatic impairment is expected to reduce drug clearance and prolong both the duration and intensity of pharmacological effects.

No formal Child-Pugh-based dosing data exists for hyoscine hydrobromide.

The following guidance is based on pharmacokinetic principles:

Child-Pugh Class	Dose Adjustment	Notes
A (Mild)	No formal adjustment. Use standard doses with clinical monitoring.	Monitor for prolonged sedation and excessive anticholinergic effects. In practice, single-dose use (premedication, PONV) is unlikely to be significantly affected.
B (Moderate)	⚠️ Reduce dose by 25–50%. Use lower end of dose range.	The drug’s hepatic conjugation pathways are likely impaired. Expect prolonged duration of action. In chronic use (sialorrhoea, palliative care), increase the dosing interval (e.g., from every 6 hours to every 8–12 hours). Monitor for CNS depression, confusion, and excessive sedation — especially problematic in patients with hepatic encephalopathy where anticholinergic-induced delirium may mimic worsening encephalopathy.
C (Severe)	⚠️ Avoid if possible. If essential (e.g., terminal secretions in palliative care), use minimum effective dose with close clinical monitoring.	Markedly reduced clearance expected. Risk of prolonged and profound anticholinergic effects. Hypoalbuminaemia in severe liver disease increases free drug fraction (though protein binding is ~50%, significant enough that hypoalbuminaemia could increase pharmacological effect). In palliative care for patients with hepatocellular carcinoma/cirrhosis with terminal secretions, use the lowest effective dose of glycopyrrolate as an alternative if peripheral antisecretory effect alone is sufficient.

No formal hepatic dosing data available. Clinical guidance based on pharmacokinetic principles.

Active metabolite accumulation: No clinically significant active metabolites. Accumulation of inactive conjugated metabolites in hepatic impairment is not expected to cause additional pharmacological effects (though renal clearance of these metabolites may also be reduced in combined hepato-renal dysfunction — hepatorenal syndrome).

Concurrent hepatotoxin note: Hyoscine hydrobromide itself is not hepatotoxic. No specific concern regarding additive hepatotoxicity when co-administered with rifampicin, isoniazid, pyrazinamide, methotrexate, valproate, or antiretrovirals. However, rifampicin (a potent enzyme inducer) may theoretically increase the clearance of hyoscine hydrobromide by inducing conjugation pathways, potentially reducing its efficacy — though this interaction has not been formally studied or documented as clinically significant.

CONTRAINDICATIONS

⛔ Absolute contraindications — the drug must NEVER be used in these situations:

Contraindication	Clinical Rationale
⛔ Known hypersensitivity to hyoscine hydrobromide, other belladonna alkaloids (atropine, homatropine), or any excipient in the formulation	Risk of anaphylaxis or severe hypersensitivity reaction. Cross-reactivity exists among belladonna alkaloids (atropine, hyoscyamine, scopolamine) — all are tropane alkaloids with structural similarity. Cross-reactivity rate is high (structure-based, predictable). If a patient has a documented allergy to atropine, assume cross-reactivity with hyoscine hydrobromide and do not administer. Glycopyrrolate (a synthetic quaternary ammonium compound, structurally unrelated to belladonna alkaloids) is a safe alternative in this situation.
⛔ Narrow-angle (angle-closure) glaucoma — untreated or uncontrolled	Muscarinic blockade causes mydriasis, which pushes the peripheral iris forward and obstructs the trabecular meshwork outflow pathway, precipitating an acute rise in intraocular pressure. This can cause acute angle-closure crisis — an ophthalmological emergency that can result in permanent visual loss within hours if untreated. ℹ️ Note: Patients with open-angle glaucoma on adequate treatment are NOT absolutely contraindicated — hyoscine can be used with caution and IOP monitoring. The contraindication applies specifically to anatomically narrow angles or known angle-closure glaucoma.
⛔ Myasthenia gravis	Anticholinergic agents antagonise the therapeutic effect of acetylcholinesterase inhibitors (pyridostigmine, neostigmine) that are the mainstay of myasthenia gravis treatment. Administration of hyoscine hydrobromide can precipitate a myasthenic crisis (acute worsening of muscle weakness, including respiratory muscles, potentially requiring intubation).
⛔ Paralytic ileus or gastrointestinal obstruction (mechanical — where prokinesis is needed)	Anticholinergic effects reduce gastrointestinal motility and secretions, worsening existing obstruction and delaying diagnosis/management. ℹ️ Exception: In inoperable malignant bowel obstruction managed palliatively, hyoscine hydrobromide is specifically used TO reduce secretions and peristalsis as part of conservative management — this is NOT a contraindication in the palliative context (see Secondary Indication 4 in Part 2). The contraindication applies to mechanical obstruction where surgical or interventional management is being considered.
⛔ Urinary retention due to obstructive uropathy (complete urinary obstruction)	Anticholinergic blockade of the detrusor muscle worsens urinary retention. In patients with complete urinary obstruction (e.g., from large prostatic enlargement, urethral stricture, or pelvic mass), hyoscine hydrobromide can precipitate acute urinary retention requiring emergency catheterisation. ℹ️ Patients with mild-to-moderate prostatic symptoms (incomplete obstruction) are listed under Cautions, not here.
⛔ Megacolon (toxic or non-toxic)	Anticholinergic agents can worsen colonic dilation, increase the risk of perforation, and delay the recognition of peritonitis in toxic megacolon (e.g., in ulcerative colitis, Clostridioides difficile infection).
⛔ Tachyarrhythmia — uncontrolled (e.g., atrial fibrillation with rapid ventricular response, supraventricular tachycardia, ventricular tachycardia)	Hyoscine’s vagolytic effect further increases heart rate and can exacerbate or destabilise the arrhythmia. In unstable tachyarrhythmias, additional heart rate acceleration can precipitate haemodynamic collapse.
⛔ Phaeochromocytoma	Anticholinergic-induced tachycardia in the setting of catecholamine excess can precipitate hypertensive crisis or cardiac arrhythmia.

Allergy cross-reactivity summary:

Drug/Class	Cross-reactivity with Hyoscine Hydrobromide	Approximate Rate	Nature
Atropine	YES — high	Very high (~100% structural similarity as tropane alkaloids)	Structure-based (predictable)
Hyoscyamine (levoscopolamine)	YES — high	Very high	Structure-based (predictable — stereoisomer)
Homatropine	YES — moderate-high	High	Structure-based (semi-synthetic tropane)
Hyoscine butylbromide	YES — likely	Moderate-high (quaternary derivative of hyoscine)	Structure-based
Tropicamide	LOW	Low (<5%)	Different chemical class (synthetic, non-tropane); cross-reactivity is rare but has been reported
Cyclopentolate	LOW	Low	Different chemical class
Glycopyrrolate	NONE expected	Nil — structurally unrelated (synthetic quaternary ammonium)	Safe alternative in tropane alkaloid allergy
Ipratropium, tiotropium	VERY LOW	Very low — different quaternary ammonium structure	Theoretical only; clinical cross-reactivity with tropane alkaloids is not documented

CAUTIONS

⚠️ HIGH-PRIORITY CAUTIONS (serious harm possible without active monitoring or dose adjustment):

Condition	Risk	Required Monitoring / Action
⚠️ Elderly patients (≥60 years)	Exaggerated central and peripheral anticholinergic effects — delirium, confusion, hallucinations, falls (from postural hypotension and impaired balance), urinary retention, severe constipation, worsened cognitive impairment. Pharmacokinetic (reduced clearance) and pharmacodynamic (reduced cholinergic reserve) factors both contribute.	Reduce dose by 50%. Use the lowest effective dose. Monitor mental status actively (CAM-ICU or equivalent delirium screening) for 24 hours after administration. Prefer glycopyrrolate if central effects are undesirable. See dedicated ELDERLY section for full details.
⚠️ Pre-existing cognitive impairment or dementia	⛔ Near-absolute contraindication. Anticholinergic drugs worsen cognitive function in patients with Alzheimer’s disease, vascular dementia, Lewy body dementia, and Parkinson’s disease dementia. Patients on cholinesterase inhibitors (donepezil, rivastigmine, galantamine) will have their therapeutic effect directly antagonised.	Avoid unless absolutely essential (e.g., terminal secretions in palliative care where the patient is in the dying phase). If used, expect significant cognitive deterioration and increased confusion. Do NOT co-prescribe with cholinesterase inhibitors without explicit specialist discussion.
⚠️ Prostatic hypertrophy (BPH) without complete obstruction	Increased risk of acute urinary retention. Anticholinergic effects reduce detrusor contractility and increase outlet resistance.	Enquire specifically about urinary symptoms before prescribing. If used (e.g., for premedication), monitor urine output postoperatively. Have catheterisation available. Use the lowest effective dose. Consider glycopyrrolate as an alternative (lower risk of urinary retention, though not zero).
⚠️ Cardiac conditions — ischaemic heart disease, heart failure, compensated arrhythmias	Tachycardia increases myocardial oxygen demand. In patients with coronary artery disease, this can precipitate angina or acute myocardial ischaemia. In heart failure, tachycardia reduces diastolic filling time and worsens cardiac output.	Use the lowest effective dose. Monitor heart rate and ECG. Avoid in unstable angina or decompensated heart failure. In stable coronary disease, a single low dose for premedication (0.2 mg) is generally tolerable with monitoring.
⚠️ Autonomic neuropathy (e.g., diabetic, amyloid)	Exaggerated response to anticholinergic drugs — excessive tachycardia, postural hypotension, gastroparesis worsening, urinary retention. Autonomic neuropathy alters baseline parasympathetic tone, making the effects of muscarinic blockade unpredictable.	Reduce dose by 50%. Monitor heart rate and blood pressure (lying and standing) for at least 30 minutes after parenteral administration.
⚠️ Down syndrome (Trisomy 21)	Increased sensitivity to anticholinergic agents — both adults and children with Down syndrome show exaggerated mydriasis, tachycardia, and hyperthermia responses. CNS excitatory responses (agitation, hallucinations) are more common.	Use 50% of the standard dose. Monitor closely. Prefer glycopyrrolate for antisialagogue effect. This is especially relevant in Indian practice, as many Down syndrome patients present for cardiac surgery (congenital heart defects) where anticholinergic premedication is commonly considered.
⚠️ Pyrexia (fever) or high ambient temperature	Anticholinergic drugs suppress sweating, impairing thermoregulation. In febrile patients or in hot environmental conditions (common across India for much of the year), this can precipitate life-threatening hyperthermia, especially in children, elderly, and labourers with outdoor exposure.	⚠️ Monitor temperature actively. Ensure the patient is in a cooled environment. Provide external cooling measures if needed. Do NOT use for motion sickness prophylaxis in settings where the patient will be exposed to high ambient temperatures without access to cooling.
⚠️ Gastro-oesophageal reflux disease (GORD)	Anticholinergics reduce lower oesophageal sphincter (LOS) tone, worsening gastro-oesophageal reflux and increasing aspiration risk — particularly dangerous in the perioperative setting.	Consider alternatives. If used for premedication in a GORD patient, ensure aspiration prophylaxis is in place (proton pump inhibitor premedication, rapid sequence induction if appropriate).
⚠️ Hepatic impairment (Child-Pugh B or C)	Reduced drug clearance — risk of prolonged and excessive anticholinergic effects. See dedicated HEPATIC ADJUSTMENT section.	Reduce dose; extend dosing interval; monitor for prolonged sedation and anticholinergic toxicity.
⚠️ Concomitant use of other anticholinergic drugs	Additive anticholinergic burden — risk of anticholinergic toxicity syndrome (hyperthermia, delirium, tachycardia, dry flushed skin, urinary retention, ileus, seizures). Common co-prescribed anticholinergic drugs in Indian practice: antihistamines (chlorpheniramine, hydroxyzine, promethazine), tricyclic antidepressants (amitriptyline — very commonly prescribed in India), antipsychotics (olanzapine, quetiapine, chlorpromazine), antispasmodics (dicyclomine, hyoscine butylbromide), antiparkinsonians (trihexyphenidyl), muscle relaxants (orphenadrine), bladder antimuscarinics (oxybutynin, tolterodine).	⚠️ Review the patient’s full medication list for anticholinergic drugs before prescribing. Calculate cumulative anticholinergic burden if possible. Avoid combination unless essential. If combination is unavoidable, use the lowest dose of each agent and monitor closely.

STANDARD CAUTIONS (conditions needing awareness but carrying lower risk):

Condition	Notes
Hiatus hernia with reflux	Reduced LOS tone may worsen reflux symptoms. Use with awareness.
Ulcerative colitis	Risk of precipitating ileus or toxic dilation (though absolute contraindication applies only to established toxic megacolon). Use cautiously; monitor bowel function.
Chronic lung disease / COPD	Anticholinergic reduction of tracheobronchial secretions may lead to inspissation (thickening) of secretions, potentially worsening mucus plugging. However, this is usually clinically insignificant at standard doses. Paradoxically, the antisecretory effect may be beneficial for excessive secretions.
Hypertension — controlled	Monitor blood pressure; tachycardia may worsen blood pressure control in some patients. Generally safe at single doses.
Hyperthyroidism	Patients with hyperthyroidism have increased sensitivity to tachycardia-inducing effects of anticholinergics. Use lower doses; monitor heart rate.
Children <6 years	Risk of paradoxical excitation (agitation, hallucinations, seizures). Risk of hyperthermia. See dedicated PAEDIATRIC DOSING section.
Patients performing tasks requiring alertness	Hyoscine hydrobromide causes drowsiness, impaired concentration, and blurred vision. Patients must not drive, operate heavy machinery, or perform tasks requiring fine visual acuity for at least 6 hours after parenteral dosing, or for the duration of transdermal patch use plus 24 hours after removal.
Contact lens wearers	Anticholinergic-induced reduction in tear production (dry eyes) may cause contact lens discomfort. Remove lenses before ophthalmic instillation. For systemic use, advise patients of possible dry eye symptoms.
Epilepsy	May lower seizure threshold at high doses or in overdose. Use cautiously in patients with known epilepsy. Not a significant concern at standard therapeutic doses.
Renal impairment (mild-moderate)	See RENAL ADJUSTMENT section. Minor concern; monitor for accumulation of inactive metabolites.

PREGNANCY

Parameter	Details
Overall safety statement	⚠️ Use with caution — only if benefit clearly outweighs risk. Hyoscine hydrobromide crosses the placental barrier. Human data on teratogenicity is limited. Animal studies have shown some evidence of embryotoxicity at high doses, but no consistent pattern of malformations. The drug is not classified as a known human teratogen, but the evidence base is insufficient to confirm safety in early pregnancy. (Former US-FDA category C — animal studies showed adverse effects; no adequate human studies.)
Teratogenicity window	No specific developmental window of peak teratogenic risk has been identified for hyoscine hydrobromide, as there is no established pattern of structural malformations. The general period of highest vulnerability for any drug-induced organogenesis defects is weeks 3–8 post-conception (weeks 5–10 of gestational age). Avoid non-essential use during this period.
First trimester risks	Theoretical risk of embryotoxicity based on animal data. No confirmed human teratogenicity pattern. Avoid unless essential (e.g., premedication for emergency surgery where alternatives are unsuitable).
Second trimester risks	No specific documented risk. If used for essential indications (e.g., surgery during pregnancy), standard maternal monitoring applies.
Third trimester and peripartum risks	⚠️ Fetal tachycardia: Hyoscine hydrobromide crosses the placenta and can cause fetal tachycardia, which may be misinterpreted on CTG (cardiotocography) as fetal distress, leading to unnecessary interventions. ⚠️ Reduced fetal heart rate variability: Anticholinergic-induced suppression of beat-to-beat variability may mask genuine fetal compromise on CTG monitoring. ⚠️ Neonatal effects: If given close to delivery, the neonate may exhibit anticholinergic effects — tachycardia, feeding difficulty (dry mouth), reduced gastrointestinal motility, temperature instability, drowsiness, and respiratory depression (especially if combined with opioids).
Use in labour	Hyoscine hydrobromide has been historically used in labour for its sedative/amnestic effects (“twilight sleep” — combined with morphine) and to relax the cervix. This practice is now largely abandoned due to unpredictable maternal sedation, neonatal depression, and the availability of safer alternatives (epidural analgesia). ℹ️ In some Indian district hospitals, hyoscine hydrobromide injection may still be used as a cervical dilator or to reduce cervical spasm. Current evidence does NOT support this practice, and safer alternatives (epidural, parenteral opioids with appropriate monitoring) are recommended.
Preferred alternatives in Indian obstetric practice	For motion sickness in pregnancy: meclizine (considered relatively safe; available in India) or non-pharmacological measures (ginger, acupressure). For premedication during emergency surgery in pregnancy: glycopyrrolate (does not cross placenta — quaternary amine; preferred antisialagogue in obstetric anaesthesia). For nausea/vomiting of pregnancy: doxylamine + pyridoxine (first line); ondansetron (second line after first trimester).
What to monitor (mother)	Heart rate (tachycardia), blood pressure, temperature, urinary output, level of consciousness.
What to monitor (fetus/neonate)	CTG monitoring during and after maternal administration — anticipate fetal tachycardia and reduced beat-to-beat variability; interpret CTG with this in mind. If the drug was given within 4 hours of delivery, monitor the neonate for tachycardia, feeding difficulty, temperature instability, abdominal distension, and drowsiness for at least 24 hours after birth.
Pre-conception counselling	No specific pre-conception washout or folate supplementation is required for hyoscine hydrobromide. The drug is not used chronically in the pre-conception period in most cases.
Contraception requirement	No mandatory contraception during treatment (unlike teratogenic drugs such as isotretinoin, methotrexate, or thalidomide). However, women of childbearing age using transdermal patches chronically (e.g., for sialorrhoea) should be counselled about the limited pregnancy safety data and should inform their prescriber immediately if pregnancy is planned or suspected.

Pregnancy Prevention Programme / Registry:

Not applicable — hyoscine hydrobromide does not have a mandatory pregnancy prevention programme or pregnancy exposure registry in India or internationally.

Fertility Effects:

No known significant effect on male or female fertility at therapeutic doses. Animal reproduction studies have not shown consistent adverse effects on fertility parameters. No specific washout period before planned conception is required.

ℹ️ Theoretical concern: High-dose or prolonged anticholinergic use could theoretically affect cervical mucus quality (by reducing glandular secretions), but this has not been demonstrated to impair fertility in clinical practice.

LACTATION

Parameter	Details
Compatibility with breastfeeding	⚠️ Use with caution. Small amounts of hyoscine hydrobromide are excreted into breast milk. Single-dose use (e.g., premedication for surgery) is generally considered compatible with breastfeeding after a brief observation period. Chronic or repeated dosing during breastfeeding is not recommended due to potential for infant anticholinergic effects.
Drug levels in milk	Data limited. Qualitatively: low-to-moderate transfer into breast milk is expected (low molecular weight, moderate lipophilicity, moderate protein binding — all factors favour some milk transfer). Relative Infant Dose (RID): not formally established for hyoscine hydrobromide. Some estimates suggest the RID is likely <10% (generally considered acceptable), but confidence in this estimate is low due to limited data.
What to monitor in the infant	Drowsiness or excessive sleepiness, poor feeding or reduced suckling, irritability or unexplained crying (paradoxical excitation — possible in young infants), dry mouth (may manifest as difficulty latching or reduced saliva), tachycardia (if measured), reduced urine output (check nappy wetness), abdominal distension or reduced stool frequency, fever or flushing (impaired sweating).
Timing advice	If a single dose is used (e.g., for postoperative period): take the dose immediately after a feed and wait at least 4–6 hours before the next breastfeed to minimise peak milk drug levels at the time of the next feed. Express and discard milk during this period if engorgement occurs.
Preferred alternatives during lactation	For antisecretory/premedication: glycopyrrolate — quaternary amine, does not cross into breast milk significantly, minimal systemic absorption from GI tract even if ingested by infant via milk. Strongly preferred for breastfeeding mothers. For motion sickness: meclizine (considered compatible with breastfeeding, L2 rating in Hale’s). For PONV: ondansetron (minimal milk transfer, considered compatible).

Effect on milk production:

⚠️ Anticholinergic drugs may reduce milk production. Prolactin secretion itself is not directly affected by muscarinic blockade, but anticholinergic-induced reduction in glandular secretory activity may reduce milk letdown and volume. This effect is more likely with chronic use than with single doses.

ℹ️ Conversely, some older literature suggests that anticholinergics, by reducing dopaminergic tone indirectly, could paradoxically increase prolactin — but this is not a clinically reliable or consistent effect.

Clinical recommendation: Avoid chronic use of hyoscine hydrobromide during breastfeeding. If a single dose is essential, monitor milk supply over the following 48 hours.

Temporary incompatibility guidance (single-dose use):

Scenario	Guidance
Single parenteral dose (premedication/PONV)	Withhold breastfeeding for 4–6 hours after the dose. Express and discard milk during this period if needed for comfort (pump and discard). Resume breastfeeding after 4–6 hours if the mother is alert and the infant shows no adverse effects at the next feed.
Transdermal patch (single application for travel)	While the patch is on, monitor the infant for drowsiness and poor feeding. If the infant shows signs of anticholinergic effects, remove the patch and withhold breastfeeding for 24 hours after patch removal (residual skin depot continues to release drug). Consider pump and discard during this period.
Chronic transdermal or oral use (sialorrhoea management)	⚠️ Not recommended during breastfeeding. Switch to glycopyrrolate if antisialagogue therapy is essential during lactation.

ELDERLY

Definition: ≥60 years (consistent with Indian Census and National Programme for Health Care of the Elderly). Where specific drug data uses a different threshold, it is noted.

⚠️ Hyoscine hydrobromide carries a HIGH RISK of adverse effects in elderly patients. This is one of the most important clinical considerations for this drug.

Parameter	Details
Recommended starting dose	0.1–0.2 mg IM/SC/IV (50% of the standard adult dose) as a single dose. For the rare situation where oral dosing is used: 0.15 mg (half a 0.3 mg tablet). Do NOT use the standard adult dose (0.4–0.6 mg) in patients ≥60 years.
Titration	Not applicable for single-dose use (premedication, PONV). For chronic use in palliative care: start at the lower end of the dose range and titrate upward only if clinical effect is inadequate and adverse effects are acceptable. Titration interval: wait at least 8–12 hours (longer than in younger adults) before dose escalation, to allow for the slower clearance in elderly.
Key risks in elderly	1. Delirium and acute confusion — the most important risk. Anticholinergic drugs are one of the most common precipitants of delirium in hospitalised elderly patients. Hyoscine hydrobromide is particularly deliriogenic because it crosses the BBB. Risk is further compounded by: polypharmacy (cumulative anticholinergic burden), pre-existing cognitive impairment (even subclinical), dehydration, infection, postoperative state, electrolyte abnormalities. 2. Falls — drowsiness, impaired balance, postural hypotension, and blurred vision all increase fall risk. 3. Urinary retention — prostatic hypertrophy (common in elderly Indian males), concurrent alpha-blockers or anticholinergics increase risk. 4. Constipation and ileus — especially in immobile, dehydrated elderly patients or those on opioids. 5. Tachycardia — may be poorly tolerated in the elderly heart (reduced cardiac reserve, ischaemic heart disease). 6. Dry mouth — worsens oral hygiene, denture comfort, and swallowing in elderly patients. 7. Blurred vision — impairs reading, recognising faces, and navigating — contributing to falls and social isolation. 8. Paradoxical agitation — more common in elderly with dementia than in younger adults. 9. Cognitive worsening — even a single dose may produce measurable cognitive impairment lasting 24–48 hours in elderly patients.

Anticholinergic Cognitive Burden (ACB):

⚠️ Hyoscine hydrobromide has a HIGH anticholinergic burden — ACB Score 3 (definite anticholinergic activity, clinically significant cognitive effects).

ACB Score 3 drugs are the most potent anticholinergics and are associated with:

Increased risk of cognitive decline with chronic use
Increased risk of all-cause dementia with cumulative exposure
Increased mortality in some observational studies of elderly patients

Cumulative anticholinergic burden assessment: Before prescribing hyoscine hydrobromide to any elderly patient, review the entire medication list for other anticholinergic drugs and calculate the total ACB score. Common offenders in Indian elderly patients include:

Drug	ACB Score	Common Indian Indication
Amitriptyline	3	Neuropathic pain, depression, migraine prophylaxis
Chlorpheniramine	3	Allergic rhinitis, common cold
Hydroxyzine	3	Anxiety, pruritus, sedation
Oxybutynin	3	Overactive bladder
Promethazine	3	Antiemetic, sedation, allergy
Dicyclomine	3	Irritable bowel syndrome
Olanzapine	2	Psychosis, bipolar disorder
Ranitidine	1	Acid peptic disease
Metformin	0	Diabetes — no anticholinergic burden

ℹ️ A total ACB score ≥3 from all medications combined is associated with clinically significant cognitive risk. Adding hyoscine hydrobromide (ACB 3) to any existing anticholinergic regimen pushes the cumulative burden dangerously high.

Beers Criteria / STOPP-START relevance:

Criteria	Recommendation
American Geriatrics Society Beers Criteria (2023)	Hyoscine (scopolamine) is listed as a drug to AVOID in older adults due to high anticholinergic burden and risk of confusion, delirium, falls, constipation, and urinary retention. Both the oral and transdermal forms are included.
STOPP Criteria (v2)	STOPP D1: Anticholinergics in patients with dementia or chronic cognitive impairment — increased risk of confusion. STOPP D2: Anticholinergics in patients with narrow-angle glaucoma. STOPP D3: Anticholinergics in patients with chronic prostatism. STOPP K1: Antimuscarinic drugs in combination with other anticholinergics.

ℹ️ These criteria are referenced as additional international guidance supporting caution, not as primary Indian guidelines. However, the clinical concerns they highlight are universally applicable.

Common clinical scenarios in elderly Indian patients:

Scenario	Guidance
Elderly patient for surgery — premedication	⚠️ Strongly prefer glycopyrrolate (0.1–0.2 mg IV/IM) as the antisialagogue premedication. It does not cross the BBB — no delirium, no cognitive impairment, no sedation. If amnesia is specifically desired, use low-dose midazolam (0.5–1 mg IV) instead of relying on hyoscine for amnesia.
Elderly patient with terminal illness — death rattle	This is the one context where hyoscine hydrobromide may be appropriate in the elderly — the patient is in the dying phase and cognitive effects are no longer a primary concern. However, even here, glycopyrrolate (0.2 mg SC every 4–6 hours or 0.6–1.2 mg/24 hours SC infusion) is preferred if the patient is still partially conscious and at risk of terminal agitation/delirium. Use hyoscine hydrobromide when concurrent sedation is specifically desired (actively dying, agitated patient).
Elderly patient with motion sickness	Avoid hyoscine hydrobromide entirely. Use meclizine 12.5–25 mg (less sedating, lower anticholinergic burden) or cinnarizine 25 mg as alternatives. Non-pharmacological measures (positioning, fresh air, visual fixation) should be the first approach.
Elderly patient on polypharmacy (5+ medications)	Calculate total anticholinergic burden before adding hyoscine. Consider medication review to reduce existing anticholinergic load before introducing another.
Elderly patient with Parkinson’s disease	⛔ Avoid — worsens cognitive function, interacts with dopaminergic therapy, and can precipitate psychosis (visual hallucinations). If antisecretory therapy is needed, use glycopyrrolate.

Deprescribing guidance:

Parameter	Details
When to consider stopping	If hyoscine hydrobromide has been initiated for sialorrhoea management in an elderly patient (off-label) or chronic motion sickness, reassess the need at every visit. If the original symptom has improved, consider stopping. If anticholinergic side effects (dry mouth, constipation, confusion, urinary symptoms) outweigh benefits, stop immediately.
Tapering schedule	Not required — hyoscine hydrobromide can be stopped abruptly if used as oral tablets or injection. For transdermal patches used continuously for >3 days: warn about cholinergic rebound symptoms (nausea, vomiting, headache, disequilibrium) and manage symptomatically. No formal taper exists, but removing the patch and monitoring for 72 hours is the standard approach.
Expected withdrawal effects	Cholinergic rebound (after prolonged transdermal use): nausea, vomiting, headache, dizziness, muscle weakness — typically self-limiting within 24–72 hours. No pharmacological dependence or addiction.

MAJOR DRUG INTERACTIONS

⛔ Interactions that are contraindicated, can cause life-threatening adverse events, or require mandatory dose adjustment / alternative drug selection.

Interacting Drug/Substance	Mechanism	Clinical Effect	Onset Type	Action Required
⛔ Other anticholinergic drugs (additive): Atropine, glycopyrrolate, hyoscine butylbromide, dicyclomine, oxybutynin, tolterodine, solifenacin, trihexyphenidyl, benztropine, ipratropium/tiotropium (systemic absorption), orphenadrine	Additive muscarinic receptor blockade at multiple organ systems	⚠️ Anticholinergic toxicity syndrome: hyperthermia, delirium, tachycardia, dry flushed skin (“red as a beet, dry as a bone, hot as a hare, blind as a bat, mad as a hatter”), urinary retention, ileus, seizures, coma. Can be fatal.	Acute onset — effects manifest within hours of co-administration	⛔ Avoid combination unless absolutely essential. If unavoidable, use the lowest dose of each drug, monitor vitals and mental status closely. Have physostigmine available for severe toxicity (see Serious Adverse Effects).
⛔ Tricyclic antidepressants (amitriptyline, nortriptyline, imipramine, doxepin, clomipramine)	Additive anticholinergic burden (TCAs have strong intrinsic anticholinergic activity — ACB 3)	⚠️ Very high risk of anticholinergic toxicity, delirium, urinary retention, paralytic ileus, hyperthermia. Additive cardiac effects (tachycardia). Especially dangerous in elderly. Amitriptyline is one of the most commonly prescribed drugs in Indian practice (pain, depression, migraine) — this combination is frequently encountered and dangerous.	Acute onset	⛔ Avoid combination in elderly. In younger adults, if unavoidable, use lowest dose of hyoscine and monitor closely. Review whether the TCA can be replaced with a less anticholinergic antidepressant (e.g., sertraline, escitalopram).
⛔ Potassium chloride oral solid preparations (sustained-release/enteric-coated KCl tablets)	Anticholinergic-induced reduced GI motility causes prolonged contact of the solid KCl formulation with the GI mucosa	⚠️ Risk of GI ulceration, stricture, and perforation — particularly in the small bowel. Well-documented drug interaction.	Gradual onset — damage occurs over days of concurrent use	⛔ Avoid concurrent use of solid oral KCl formulations with anticholinergic drugs. If potassium supplementation is needed, use liquid KCl preparations or IV potassium.
⚠️ Opioids (morphine, fentanyl, tramadol, codeine, tapentadol)	Additive CNS depression (sedation, respiratory depression) + additive reduction in GI motility (constipation, ileus)	⚠️ Risk of excessive sedation, respiratory depression (especially in elderly, obese, or sleep apnoea patients), severe constipation, and paralytic ileus. In palliative care, this combination is frequently used intentionally but requires awareness of the additive risks.	Acute onset (CNS depression); Gradual onset (constipation/ileus)	Reduce hyoscine dose when combined with opioids. Monitor respiratory rate, level of consciousness (sedation scores), and bowel function. In palliative care syringe drivers, this combination is standard — use the lowest effective dose of each, and prescribe prophylactic laxatives. Have naloxone available for opioid-predominant respiratory depression.
⚠️ Benzodiazepines and Z-drugs (midazolam, diazepam, lorazepam, zolpidem, zopiclone)	Additive CNS depression	⚠️ Excessive sedation, respiratory depression, falls (especially elderly), paradoxical disinhibition, amnesia (may be desired in premedication but can be excessive)	Acute onset	Reduce dose of both drugs. In premedication, if midazolam and hyoscine are co-administered, use low doses of each (e.g., midazolam 0.5–1 mg + hyoscine 0.2 mg IV). Monitor SpO₂ and sedation level.
⚠️ First-generation (sedating) antihistamines (chlorpheniramine, diphenhydramine, hydroxyzine, promethazine)	Additive anticholinergic + additive CNS depressant effects (both H₁-antihistamines and scopolamine cross the BBB)	⚠️ Excessive sedation, delirium (especially elderly), anticholinergic toxicity, dry mouth, urinary retention, constipation	Acute onset	Avoid combination unless essential. If an antihistamine is needed concurrently, prefer a second-generation non-sedating antihistamine (cetirizine, levocetirizine, fexofenadine — lower anticholinergic burden, no CNS depression).
⚠️ Cholinesterase inhibitors (donepezil, rivastigmine, galantamine, pyridostigmine, neostigmine)	Pharmacodynamic antagonism — hyoscine blocks the muscarinic receptors that cholinesterase inhibitors are trying to activate by increasing acetylcholine	⚠️ Loss of efficacy of the cholinesterase inhibitor. In patients with Alzheimer’s disease on donepezil/rivastigmine, adding hyoscine can cause acute cognitive deterioration. In myasthenia gravis on pyridostigmine/neostigmine, can precipitate myasthenic crisis (see Contraindications).	Acute onset	⛔ Contraindicated in myasthenia gravis. ⛔ Avoid in dementia patients on cholinesterase inhibitors unless the patient is in the actively dying phase and the benefit of secretion control outweighs cognitive concerns. If used in the palliative setting, document the clinical rationale and inform the family that cognition may worsen.
⚠️ Antipsychotics with significant anticholinergic activity (chlorpromazine, thioridazine, clozapine, olanzapine, quetiapine)	Additive anticholinergic effects + additive sedation + additive QT prolongation risk (some antipsychotics)	⚠️ Anticholinergic toxicity, excessive sedation, paralytic ileus (especially with clozapine — clozapine-induced ileus is a known fatal complication), hyperthermia, NMS-mimicking syndrome	Acute onset (sedation); Gradual onset (ileus, constipation)	⚠️ Avoid combination with clozapine if possible (risk of fatal ileus). With other antipsychotics, use lowest effective dose of hyoscine and monitor bowel function, temperature, and mental status.

Food-Drug and Herb-Drug Interactions (Major):

Substance	Mechanism	Clinical Effect	Action
Alcohol (ethanol)	Additive CNS depression	⚠️ Excessive sedation, impaired psychomotor function, respiratory depression, falls. Alcohol also impairs thermoregulation, compounding hyoscine’s suppression of sweating in hot climates.	⛔ Advise complete avoidance of alcohol during treatment and for 6 hours after parenteral dosing or while wearing transdermal patch.
Cannabis / marijuana (recreational or medicinal)	Additive CNS depression + additive tachycardia	Excessive sedation, tachycardia, disorientation, potential for hallucinations	⚠️ Avoid concurrent use.

MODERATE DRUG INTERACTIONS

Interactions that usually can be managed with monitoring or minor dose adjustment, but require awareness.

Interacting Drug/Substance	Mechanism	Clinical Effect	Onset Type	Action Required
Metoclopramide, domperidone	Pharmacodynamic antagonism — hyoscine reduces GI motility while metoclopramide/domperidone increase it	Reduced prokinetic efficacy of metoclopramide/domperidone. The antiemetic effects may be partially additive (both act centrally, but via different mechanisms).	Acute onset	ℹ️ The combination is pharmacologically antagonistic at the gut level. Avoid concurrent use if the primary goal is to promote gastric emptying. If the goal is antiemesis only, the combination may be used, but the GI motility benefit of metoclopramide will be reduced.
Antacids (aluminium/magnesium hydroxide)	Potential for altered absorption of oral hyoscine hydrobromide (pH-dependent absorption changes)	May reduce or delay absorption of oral hyoscine tablets. Clinical significance uncertain given the limited use of oral formulation.	Gradual onset	Separate administration by at least 1 hour. Give hyoscine first, then antacid after 1 hour.
Sublingual nitrates (GTN/ISDN)	Anticholinergic-induced dry mouth reduces sublingual tablet dissolution	⚠️ Reduced bioavailability of sublingual GTN — potentially dangerous in acute angina. Dry mouth prevents proper dissolution of the sublingual tablet, delaying drug absorption.	Acute onset	ℹ️ If the patient is on sublingual GTN for angina, warn that dry mouth from hyoscine may impair GTN dissolution. Advise sipping a small amount of water to moisten the mouth before placing the GTN tablet sublingually. Alternatively, use GTN spray (which does not require saliva for absorption). Adjust GTN formulation to metered-dose spray if the patient is on chronic hyoscine.
Levodopa / carbidopa-levodopa	Anticholinergics reduce GI motility, potentially delaying levodopa absorption from the GI tract	Delayed and potentially reduced levodopa absorption → worsened motor fluctuations, delayed “on” time	Gradual onset	ℹ️ Monitor Parkinson’s disease motor function. Avoid chronic co-administration. If a single dose of hyoscine is needed (e.g., premedication for surgery in a Parkinson’s patient), time the hyoscine dose at least 2 hours away from levodopa and monitor motor status postoperatively.
Digoxin (oral tablets)	Anticholinergic-induced slowed GI transit increases digoxin absorption time and may increase bioavailability of slowly-dissolving digoxin tablet formulations	Potential for modestly increased digoxin levels (clinically significant primarily with non-bioequivalent digoxin tablets)	Gradual onset	Monitor for digoxin toxicity (nausea, visual disturbance, bradycardia — note: hyoscine may mask the bradycardia). Check digoxin levels if chronic co-administration is anticipated. This interaction is primarily relevant with older tablet formulations; modern bioequivalent tablets and liquid formulations are less affected.
Topiramate	Additive reduction in sweating (topiramate inhibits carbonic anhydrase → reduced sweating; hyoscine → anticholinergic suppression of sweating)	⚠️ Oligohidrosis and hyperthermia — particularly dangerous in children and in hot Indian climate. Both drugs independently reduce sweating; the combination synergistically impairs thermoregulation.	Gradual onset	⚠️ Avoid combination in children and in hot climates if possible. If unavoidable, monitor temperature closely, ensure adequate hydration, avoid strenuous activity in heat, and counsel parents/caregivers about heat-related illness warning signs.
Pramlintide, GLP-1 receptor agonists (liraglutide, semaglutide, dulaglutide)	Anticholinergic reduction in GI motility may compound the gastroparesis-like effects of pramlintide and GLP-1 RAs	Delayed gastric emptying, increased nausea, increased risk of bezoar formation (theoretical)	Gradual onset	Monitor GI symptoms. Use hyoscine at lowest effective dose for shortest duration.
Second-generation (non-sedating) antihistamines (cetirizine, levocetirizine, fexofenadine, loratadine)	Mild additive anticholinergic effect (much less than with first-generation antihistamines)	Mild additional dry mouth, mild drowsiness (cetirizine/levocetirizine more sedating than fexofenadine)	Acute onset	Generally acceptable combination. Monitor for excessive dry mouth. Preferred over first-generation antihistamines if antihistamine is needed concurrently.
Memantine	Pharmacodynamic — both memantine and anticholinergics can impair cognition in elderly; potential for enhanced CNS effects	May worsen cognitive function in patients with dementia who are on memantine for neuroprotection	Gradual onset	⚠️ Avoid combination in patients with dementia. If a single dose is essential (palliative care), document rationale.
Corticosteroids (systemic)	Both drugs can increase intraocular pressure (corticosteroids via posterior subcapsular mechanism; hyoscine via mydriasis and aqueous outflow obstruction in predisposed eyes)	Additive risk of raised IOP, especially in patients with pre-existing narrow angles or steroid-induced glaucoma	Gradual onset	Monitor IOP in patients receiving both drugs chronically, especially those with glaucoma risk factors.
Phenothiazine antiemetics (prochlorperazine, chlorpromazine — used as antiemetic)	Additive anticholinergic + sedation	Enhanced sedation, anticholinergic effects, postural hypotension	Acute onset	Use lowest effective dose of each. Monitor vital signs and level of consciousness. In Indian practice, prochlorperazine is a very commonly prescribed antiemetic — avoid combining with hyoscine for the same indication (choose one).

Herb-Drug and Traditional Medicine Interactions (Moderate):

Substance	Mechanism	Clinical Effect	Action
Datura stramonium (dhatura — used in Ayurvedic/folk medicine as a sedative, analgesic, bronchodilator)	Contains tropane alkaloids (atropine, scopolamine, hyoscyamine) — same class as hyoscine hydrobromide	⚠️ Additive anticholinergic toxicity. Datura preparations have highly variable alkaloid content and have caused fatal poisoning in India. Combining with pharmaceutical hyoscine hydrobromide can cause severe anticholinergic syndrome. Traditional medicine interaction.	⛔ Avoid concurrent use. Ask specifically about dhatura use (common in some regions of India as a traditional remedy or intoxicant). Educate the patient that this combination is dangerous.
Belladonna-containing Ayurvedic or Unani preparations	Same mechanism as above — contain tropane alkaloids	Additive anticholinergic toxicity. Traditional medicine interaction.	⛔ Avoid. Enquire about use of traditional preparations containing belladonna, dhatura, or related plants.
Ashwagandha (Withania somnifera)	Mild sedative / GABAergic effects	Additive sedation when combined with hyoscine’s CNS depressant effect. Traditional medicine interaction.	ℹ️ Likely mild interaction. Monitor for excessive drowsiness. No dose adjustment required, but counsel about additive sedation.
Brahmi (Bacopa monnieri)	Cholinergic-enhancing effects (used as cognitive enhancer in traditional medicine and increasingly in modern practice)	Pharmacodynamic antagonism — Brahmi’s cholinergic-enhancing effects may be partially blocked by hyoscine’s anticholinergic action. Reduced cognitive benefit of Brahmi.	ℹ️ Clinical significance uncertain. If the patient is taking Brahmi for cognitive support, adding hyoscine may negate the benefit. No safety concern per se.

COMMON ADVERSE EFFECTS

ℹ️ The adverse-effect profile of hyoscine hydrobromide is dominated by its antimuscarinic pharmacology — most common effects are predictable extensions of muscarinic receptor blockade at various organ systems. Central (CNS) effects distinguish this drug from quaternary ammonium antimuscarinics (glycopyrrolate, hyoscine butylbromide) that do not cross the blood-brain barrier.

Frequency classification source: Derived from clinical trial data for the transdermal patch (best-studied formulation for adverse effect incidence) and from post-marketing surveillance for parenteral formulations. Exact percentages are approximate and vary by route, dose, and patient population.

Very Common (≥10%):

Adverse Effect	System	Notes
Dry mouth (xerostomia)	GI / Oral	The most frequently reported adverse effect across all routes and formulations (reported in up to 50–70% of patients with the transdermal patch; virtually universal with parenteral dosing at ≥0.4 mg). Dose-dependent. Usually the earliest noticeable effect. May impair sublingual drug absorption (e.g., GTN), denture comfort, and oral hygiene. Generally transient with single-dose use; persistent during chronic transdermal patch use.
Drowsiness / sedation	CNS	Very common with parenteral and oral routes (>20%). Less pronounced with the transdermal patch (steady-state delivery avoids high peak levels). Dose-dependent — more marked at doses ≥0.4 mg parenteral. Usually desired in premedication; undesirable in motion sickness prophylaxis and sialorrhoea management. Typically diminishes with continued use (partial tolerance develops over 48–72 hours of transdermal patch use).

Common (1–10%):

Adverse Effect	System	Notes
Blurred vision (cycloplegia)	Ophthalmic	Due to paralysis of the ciliary muscle (loss of accommodation) and mydriasis. More pronounced in young patients with strong accommodative power. Impairs near vision — reading, using mobile phones, fine work. Dose-dependent. Duration corresponds to the drug’s duration of action. With transdermal patch: may persist throughout patch use and for 24 hours after removal.
Mydriasis (pupil dilation)	Ophthalmic	Usually bilateral and symmetric with systemic dosing. Unilateral mydriasis (anisocoria) can occur with the transdermal patch if the patient touches the patch and then rubs one eye — this can mimic a neurological emergency (see Serious Adverse Effects).
Tachycardia	Cardiovascular	Dose-dependent. At low doses (≤0.1 mg IV), a paradoxical transient bradycardia may occur first (partial vagal stimulation at low doses before full muscarinic blockade), followed by tachycardia. At standard doses (0.3–0.6 mg), tachycardia is the predominant cardiac effect. Heart rate increase is typically 10–20 bpm. Usually well tolerated in healthy patients; may be significant in those with ischaemic heart disease, heart failure, or hyperthyroidism.
Dizziness	CNS	Vestibular and central in origin. More common with parenteral route than transdermal.
Constipation	GI	Due to reduced GI motility (smooth muscle relaxation). More relevant with repeated dosing or chronic use (transdermal patch, palliative care infusion). Usually mild with single-dose use. Can progress to ileus when combined with opioids.
Urinary hesitancy / retention	Genitourinary	Due to detrusor muscle relaxation and increased bladder outlet resistance. More common in elderly males with prostatic hypertrophy. Dose-dependent. Monitor urine output, especially postoperatively.
Skin irritation / erythema at patch site	Dermatological	Specific to transdermal formulation. Occurs in approximately 5–10% of patch users. Usually mild, localised erythema and pruritus at the application site. Rotate application site (alternate ears) with each new patch. If persistent or severe, switch to alternative formulation or drug.
Impaired concentration / cognitive slowing	CNS	Detectable on neurocognitive testing even when subjective drowsiness is mild. Impairs short-term memory, attention, and reaction time. Particularly relevant for patients needing to remain cognitively functional (students, professionals, drivers). Dose-dependent. More pronounced in elderly.
Headache	CNS	Reported with transdermal patch — both during use and after removal (see rebound/withdrawal).
Nausea	GI	Paradoxical — though hyoscine is an antiemetic, nausea can occur, especially upon abrupt withdrawal of the transdermal patch (cholinergic rebound). During active treatment, nausea is uncommon.

Dose-Response Thresholds:

Adverse Effect	Dose Threshold
Dry mouth	Clinically significant at virtually all therapeutic doses; severity increases above 0.2 mg parenteral
Drowsiness	Mild at 0.2 mg IV/IM; moderate-to-marked at ≥0.4 mg; usually minimal at transdermal steady-state levels
Tachycardia	Typically >10 bpm increase at doses ≥0.3 mg parenteral; minimal with transdermal patch at steady state
Urinary retention	Risk increases significantly at doses ≥0.4 mg in predisposed patients (elderly, BPH, concurrent anticholinergics)
Blurred vision	Clinically significant at virtually all therapeutic doses; more pronounced with higher doses and in younger patients with strong accommodation

SERIOUS ADVERSE EFFECTS

⚠️ Rare but clinically important — may require immediate intervention, discontinuation, or hospitalisation.

Serious Adverse Effect	Approximate Frequency	Details	Action Required
⚠️ Anticholinergic toxicity syndrome (anticholinergic poisoning)	Rare at therapeutic doses; dose-dependent risk; more common in overdose, in elderly, or when combined with other anticholinergics	Classic presentation (“atropine toxicity”): Hyperthermia (hot, dry, flushed skin — “hot as a hare”), tachycardia (“fast as a hare” — heart rate >120 bpm), mydriasis (“blind as a bat”), dry mucous membranes (“dry as a bone”), flushed skin (“red as a beet”), agitated delirium with visual hallucinations (“mad as a hatter”), urinary retention, absent bowel sounds (ileus), seizures (in severe cases), and coma. Can be fatal — death results from hyperthermia, cardiovascular collapse, or respiratory failure.	⛔ Immediate discontinuation. Supportive management: external cooling, IV fluids, benzodiazepines for seizures/agitation. Specific antidote: Physostigmine salicylate — see below.
⚠️ Delirium / acute confusional state	Common in elderly (5–15% after single dose); less common in young adults (<1%)	May present as hyperactive delirium (agitation, hallucinations, combativeness) or hypoactive delirium (withdrawn, somnolent, disoriented). Can be misdiagnosed as postoperative psychosis, stroke, or worsening dementia. Hallucinations are characteristically visual (seeing insects, people, patterns) — a hallmark of anticholinergic-induced psychosis.	Stop the drug. Ensure patient safety (fall prevention, one-to-one monitoring). Treat with low-dose haloperidol (0.5–1 mg IM/IV) for severe agitation if needed. Avoid benzodiazepines for agitation unless seizures are present (benzodiazepines may worsen confusion). Physostigmine can reverse anticholinergic delirium — see below.
⚠️ Paradoxical excitation (especially children)	1–5% in children <6 years; rare in adults	Agitation, restlessness, hyperactivity, irritability, disorientation, screaming, hallucinations, and rarely seizures — opposite of the expected sedation. More common in febrile children and those receiving concurrent CNS-active drugs.	Stop the drug. Supportive care. Benzodiazepines (midazolam 0.05–0.1 mg/kg IV) if severe agitation or seizures.
⚠️ Acute angle-closure glaucoma crisis	Very rare (<0.01%) in patients without pre-existing narrow angle; higher risk in anatomically predisposed individuals	Severe unilateral (or bilateral) eye pain, headache, nausea/vomiting, blurred vision with halos around lights, rock-hard eyeball on palpation, fixed mid-dilated pupil, markedly elevated IOP. Ophthalmological emergency — permanent visual loss can occur within hours.	⛔ Immediate ophthalmology referral. Initiate IOP-lowering treatment: topical timolol 0.5%, topical pilocarpine 2% (direct-acting cholinergic — counteracts mydriasis), oral/IV acetazolamide 500 mg, IV mannitol 20% if IOP critically elevated. Definitive treatment: laser peripheral iridotomy.
⚠️ Severe urinary retention	Uncommon; more likely in elderly males with BPH	Complete inability to void. Painful bladder distension. May progress to bilateral hydronephrosis and post-renal acute kidney injury if unrecognised.	Urinary catheterisation (in-out or indwelling). Stop the drug. Review prostate status.
⚠️ Paralytic ileus	Rare with single dose; increased risk with opioid co-administration and in postoperative patients	Absent bowel sounds, progressive abdominal distension, obstipation, nausea/vomiting. Can progress to bowel ischaemia or perforation.	Stop all anticholinergic and opioid drugs. NG tube decompression. IV fluids. Surgical consultation if signs of peritonitis.
⚠️ Severe hyperthermia	Rare; primarily in children, elderly, and in hot climates (relevant to India)	Core temperature >40°C due to suppressed sweating. Can cause heat stroke with multi-organ dysfunction (renal failure, DIC, rhabdomyolysis, hepatic failure, encephalopathy). Particularly dangerous during Indian summer (ambient temperatures 40–48°C in many regions).	⛔ Medical emergency. Immediate aggressive external cooling (ice packs, cold IV fluids, evaporative cooling). Stop the drug. ICU admission for severe cases. Dantrolene is NOT effective (not malignant hyperthermia). Physostigmine may help restore sweating — see below.
⚠️ Unilateral mydriasis (anisocoria) — from transdermal patch	1–5% of patch users	Contamination of the eye from touching the patch → unilateral pupil dilation. Can mimic third cranial nerve palsy, uncal herniation, or intracranial haemorrhage → triggering unnecessary emergency neuroimaging (CT/MRI). Well-documented in the literature as a cause of false alarms in PACU and ICU.	History of transdermal patch use resolves the diagnosis. Instil pilocarpine 1% in the affected eye — anticholinergic-induced mydriasis will NOT constrict with pilocarpine (diagnostic test: pharmacological mydriasis does not respond to 1% pilocarpine, distinguishing it from third nerve palsy where the pupil will constrict). Mydriasis resolves spontaneously within 24–48 hours after decontamination (thorough eye washing and hand washing).
Anaphylaxis / severe hypersensitivity	Very rare (<1 in 100,000)	Urticaria, angioedema, bronchospasm, hypotension, cardiovascular collapse. Cross-reactivity with other belladonna alkaloids expected.	Standard anaphylaxis management: IM adrenaline (epinephrine) 0.5 mg (adult), IV fluids, antihistamines, corticosteroids, airway management. Report to PvPI.
Seizures	Very rare; primarily in overdose or in patients with pre-existing epilepsy	Generalised tonic-clonic seizures. More likely with high doses (>1 mg IV) or in combination with other seizure threshold-lowering drugs.	IV benzodiazepines (diazepam 5–10 mg or midazolam 2–5 mg). Physostigmine may be helpful (see below). Standard seizure management protocol.
Withdrawal symptoms after prolonged transdermal use	Common after >72 hours of continuous patch use; not dangerous but distressing	Nausea, vomiting, headache, dizziness, vertigo, disequilibrium, muscle weakness — cholinergic rebound syndrome. Onset 24–48 hours after patch removal. Self-limiting in 24–72 hours.	Symptomatic management: antiemetics (ondansetron), simple analgesics (paracetamol for headache). Warn patients in advance. Not a true pharmacological dependence/withdrawal — it is a rebound of the previously suppressed cholinergic system.

⚠️ Specific Antidote — Physostigmine Salicylate:

Parameter	Details
Antidote	Physostigmine salicylate — a centrally-acting (tertiary amine) acetylcholinesterase inhibitor. It crosses the blood-brain barrier and reverses BOTH central and peripheral anticholinergic effects. It is the specific antidote for anticholinergic toxicity syndrome (from any anticholinergic drug, including hyoscine hydrobromide).
When to use	Reserved for moderate-to-severe anticholinergic toxicity with life-threatening features: severe agitated delirium with risk of self-harm, seizures, severe hyperthermia unresponsive to cooling, haemodynamically significant tachyarrhythmia. NOT for routine mild anticholinergic side effects (dry mouth, blurred vision, mild drowsiness).
Adult dose	0.5–2 mg IV administered slowly over 5 minutes (no faster than 1 mg/minute). May repeat after 20–30 minutes if symptoms persist. Total dose should not exceed 4 mg in the first hour.
Paediatric dose	0.02 mg/kg IV (maximum 0.5 mg per dose) administered slowly over 5 minutes. May repeat after 5–10 minutes. Maximum total dose: 2 mg.
Contraindications to physostigmine	⛔ Asthma or reactive airway disease (risk of severe bronchospasm). ⛔ Mechanical bowel or urinary obstruction (cholinergic stimulation against obstruction). ⛔ Cardiac conduction defects (risk of bradycardia, heart block, asystole). ⛔ Co-ingestion with tricyclic antidepressants (physostigmine + TCA can cause fatal cardiac arrhythmia — obtain ECG before giving; if QRS >100 ms, do NOT give physostigmine). ⛔ Gangrene or peripheral vascular disease (cholinergic vasoconstriction).
Monitoring during physostigmine administration	Continuous ECG monitoring (watch for bradycardia, heart block). Monitor respiratory status (bronchospasm). Have atropine 0.5 mg IV ready as a reversal agent for excessive cholinergic effects from physostigmine.
Availability in India	⚠️ Limited availability. Physostigmine salicylate injection is not widely stocked in most Indian hospitals. It may be available at tertiary care centres and medical college hospitals. Alternative if physostigmine is unavailable: Supportive care is the mainstay — external cooling, benzodiazepines for agitation/seizures, IV fluids. Neostigmine (which does NOT cross the BBB) will reverse only peripheral anticholinergic effects (tachycardia, ileus, urinary retention) but NOT central effects (delirium, seizures). Neostigmine 0.5–2.5 mg IV may be considered for severe peripheral effects if physostigmine is unavailable.

ℹ️ Note on neostigmine vs physostigmine: Neostigmine is a quaternary amine — it does not cross the blood-brain barrier. It reverses peripheral anticholinergic effects only (tachycardia, ileus, urinary retention, mydriasis). It does NOT reverse central effects (delirium, hallucinations, seizures, coma). Physostigmine is a tertiary amine — it crosses the BBB and reverses both central and peripheral effects. For hyoscine hydrobromide toxicity (which is predominantly central), physostigmine is the specific antidote.

⚠️ Report to nearest ADR Monitoring Centre under PvPI (Pharmacovigilance Programme of India) or via the ADR reporting form on CDSCO website — for ALL serious adverse effects listed above. Reporting can be done at: https://www.ipc.gov.in (Indian Pharmacopoeia Commission — National Coordinating Centre for PvPI) or through the PvPI toll-free helpline.

MONITORING REQUIREMENTS

Baseline (Before Starting)

Parameter	Grade	Details
Heart rate	MANDATORY	Document baseline heart rate. Identify pre-existing tachycardia (>100 bpm) or bradycardia (<50 bpm).
Blood pressure (lying and standing)	RECOMMENDED	Especially in elderly patients and those on antihypertensives. Identify postural hypotension.
Assessment for narrow-angle glaucoma	MANDATORY	Ask specifically: “Have you been told you have glaucoma or narrow angles in your eyes?” In patients with no prior eye examination, check for shallow anterior chamber by oblique illumination (penlight test) if ophthalmological assessment is not available. If in doubt, defer to ophthalmology opinion before administering.
Prostate symptom assessment (males ≥50 years)	MANDATORY	Ask about urinary hesitancy, frequency, nocturia, poor stream, incomplete voiding. If significant symptoms exist, consider alternative drug or ensure catheterisation is available.
Cognitive status / mental state (elderly ≥60 years)	RECOMMENDED	Document baseline orientation and cognitive status using a simple bedside tool (AMT-4, 4AT, or CAM) before drug administration. This allows detection of drug-induced cognitive change postoperatively.
Temperature	RECOMMENDED	Document baseline temperature. Particularly important in children, elderly, febrile patients, and when ambient temperature is high.
Medication review for anticholinergic burden	MANDATORY	Review the full medication list. Identify concurrent anticholinergic drugs. Calculate approximate cumulative ACB score. Identify concurrent opioids, benzodiazepines, and other CNS depressants.
ECG	OPTIONAL but helpful	Not mandatory for a single dose in a healthy patient. RECOMMENDED in: elderly patients, those with cardiac history, those on QT-prolonging drugs, those on digoxin.
Serum electrolytes	OPTIONAL	Not required routinely. Consider in patients on diuretics or at risk of hypokalaemia (anticholinergic-induced constipation and ileus are worsened by hypokalaemia).
Intraocular pressure (IOP)	MANDATORY for ophthalmic use	Slit lamp and IOP measurement before instilling any cycloplegic/mydriatic agent, especially in patients >40 years.

Resource-limited setting surrogates:

Parameter	Surrogate if Test Unavailable
ECG	Palpate pulse for rate and regularity. Auscultate heart for murmurs or irregular rhythm.
Cognitive assessment tool	Ask 3 simple orientation questions: “What is your name? Where are we? What is today’s date?” Document the answers.
IOP measurement	Perform digital tonometry (gentle bimanual palpation of the globe through closed eyelids) — very approximate but can identify grossly elevated IOP. ⚠️ This is NOT a substitute for formal tonometry if available.
Prostate assessment	IPSS (International Prostate Symptom Score) is a simple questionnaire requiring no equipment — can be administered verbally.

After Initiation / Dose Change

Timing	Monitoring	Details
During and 30–60 minutes after parenteral administration	Heart rate, SpO₂, level of consciousness, blood pressure	Continuous or every 5-minute monitoring during IV administration. Every 15-minute monitoring for 30–60 minutes after IM/SC administration.
2–4 hours after parenteral dose	Mental status, temperature, urinary output	Recheck orientation (especially in elderly). Measure temperature. Confirm patient has voided (if ≥4 hours without voiding postoperatively, assess for retention).
First 24 hours of transdermal patch application	Drowsiness, dry mouth, blurred vision, skin irritation at patch site	Counsel the patient to report visual disturbance, excessive drowsiness, or difficulty voiding. Check patch adhesion.
After dose increase (palliative care continuous infusion)	Heart rate, level of consciousness, temperature, bowel sounds, urinary output	Reassess within 4–6 hours of dose increase.

Long-Term / Maintenance Monitoring

Timing	Monitoring	Details
Weekly (first month of transdermal patch use for sialorrhoea)	Dry mouth severity, cognitive function, swallowing assessment, bowel function, urinary symptoms, skin integrity at patch site	Assess whether the dry mouth is so severe that it paradoxically worsens swallowing. Check for constipation. Inspect patch sites for skin breakdown.
Monthly thereafter	Clinical review of indication, adverse effects, and ongoing need	Reassess whether sialorrhoea management is still needed. Consider trial of patch removal to reassess symptom severity without treatment.
Every 3–6 months	Full medication review including anticholinergic burden assessment	Especially important in elderly patients. Reassess need for continued therapy. Consider deprescribing.

Therapeutic Drug Monitoring (TDM)

Not applicable — hyoscine hydrobromide does not have a defined therapeutic plasma concentration range, and TDM is not performed in clinical practice. Dosing is adjusted based on clinical response and tolerability.

When to Stop Monitoring

Single-dose use (premedication, PONV): Monitoring can be discontinued once the patient is fully alert, haemodynamically stable, has voided, and has no signs of anticholinergic toxicity — typically 4–6 hours after parenteral dose (longer in elderly: 8–12 hours).
Transdermal patch (single application for motion sickness): Monitoring can be relaxed 24 hours after patch removal (residual skin depot effect).
Chronic use (sialorrhoea, palliative care): Continue monitoring throughout the duration of therapy.

PATIENT COUNSELLING

Written in simple language that a doctor can directly convey to the patient during consultation.

What this medicine is for:

“This medicine is used to prevent vomiting and dizziness during travel (motion sickness), to dry up extra saliva or secretions before an operation, or to control excess secretions in patients with serious illness. It works by blocking a chemical messenger in your body that controls saliva, stomach juices, and the balance centre in your brain.”

How to take it:

Tablet: “Swallow the tablet whole with a glass of water. You can take it with or without food. For travel sickness, take it 30 minutes before your journey begins.”
Patch: “Stick the patch on the clean, dry skin behind your ear (the hairless area). Press firmly for 10–15 seconds. Wash your hands thoroughly with soap and water after touching the patch. Replace the patch every 3 days. When you remove the old patch, fold it in half with the sticky side inward and throw it away safely where children or pets cannot reach it. Put the new patch behind the other ear.”
Injection: “This will be given to you by a doctor or nurse. You do not need to do anything.”
Eye drops: “The doctor or nurse will put the drops in your eye. After the drops are put in, press gently on the inner corner of your eye (near your nose) for 2–3 minutes. This stops the medicine from going into your body through your tear duct.”

What to do if you miss a dose:

Tablet (for travel sickness): “If you forget to take it before travel, take it as soon as you remember. But if your next dose is due within 3 hours, skip the missed dose and take the next one on time. Never take two doses together.”
Patch: “If your patch falls off or you forget to replace it, put on a new patch as soon as you remember. Do not put on two patches at the same time.”

Common side effects to expect:

“This medicine commonly causes: dry mouth (your mouth may feel very dry — sip water frequently, suck on ice chips, or use sugar-free candy to help); drowsiness (you may feel sleepy — this usually gets better after a day or two); blurred vision (things may look fuzzy, especially things close to you — do not drive or read until your vision is clear again); difficulty passing urine (tell your doctor if you cannot pass urine for more than 6 hours); constipation (drink plenty of water and eat fibre-rich foods).”

ℹ️ “Most of these side effects are mild and go away on their own after the medicine wears off.”

Warning signs — come to hospital immediately if you notice:

"⚠️ Go to the hospital immediately if you develop any of the following:

Severe confusion, seeing things that are not there (hallucinations), or unusual behaviour
Very fast heartbeat or feeling your heart racing
High fever with dry, hot skin and no sweating (especially in summer)
Inability to pass urine for more than 8 hours
Severe stomach pain with bloating and no gas passage
Severe eye pain, headache with blurred vision and coloured halos around lights (this could be a serious eye problem — it is an emergency)
Skin rash, swelling of face/lips/tongue, or difficulty breathing (this could be an allergic reaction)"

Things to avoid:

“⛔ Do not drink alcohol while using this medicine — it will make drowsiness much worse and can be dangerous.”
“⛔ Do not drive, ride a motorcycle, operate machinery, or do any work that needs full alertness while using this medicine. Wait at least 6 hours after an injection, or until 24 hours after removing the patch.”
“⚠️ Avoid very hot environments (direct sunlight, working outdoors in summer, hot kitchens, saunas) — this medicine reduces your ability to sweat, and you may overheat. Drink plenty of water. Stay in a cool place.”
“⚠️ Do not touch your eyes after handling the patch — the medicine can get into your eye and cause your pupil to widen (one eye may look bigger than the other). This is not dangerous but can be frightening. Wash your hands thoroughly after handling the patch.”

Storage:

“Store tablets and patches at room temperature, in a dry place, away from direct sunlight.”
“In very hot weather (above 30°C), keep medicines in the coolest part of the house — not in the bathroom, not in a car, and not near a window.”
“Keep all medicines away from children.”

Duration:

“For travel sickness: this medicine is used only when needed — before and during travel. It is not for daily long-term use.”
“For operations: this is given as a single dose. You do not need to continue it at home.”
“If your doctor has prescribed the patch for drooling (excess saliva): use it as directed. Do not stop suddenly without talking to your doctor — you may feel nauseous or dizzy for a few days after stopping.”

Follow-up:

“For single-dose use (before an operation or for travel): no routine follow-up blood tests are needed.”
“If you are using the patch regularly for drooling: see your doctor every 4–6 weeks initially, then every 3 months, to check whether the medicine is still needed and to watch for side effects.”

Common patient questions addressed:

Question	Answer
“Can I take this with my other medicines?”	“Tell your doctor about ALL medicines you are taking — especially medicines for sleep, anxiety, depression, pain, stomach cramps, allergy, or prostate problems. Some combinations can cause serious side effects.”
“Can I take this during fasting (Ramadan/Navratri)?”	“If you are using the tablet for travel sickness, you can take it with a small sip of water during the fasting period — most religious authorities permit medicine with water for health reasons. Discuss with your religious guide if unsure. The patch does not need to be swallowed and does not break a fast.”
“Will this affect my ability to drive or work?”	“Yes — this medicine causes drowsiness and blurred vision. Do NOT drive, ride a two-wheeler, or operate machinery while this medicine is in your system. Wait at least 6 hours after an injection, and at least 24 hours after removing a patch.”
“Is this medicine habit-forming?”	“No — this medicine is not addictive. However, if you use the patch for many days and then stop suddenly, you may feel slightly nauseous or dizzy for 1–2 days. This is temporary and not a sign of addiction.”
“Can I stop once I feel better?”	“If using it for travel sickness, stop when you no longer need it (after the journey ends). If using it for drooling, do not stop without discussing with your doctor.”

Caregiver / Family Counselling:

"If you are caring for a patient (especially a child, elderly person, or someone with a brain condition) who is receiving this medicine:

Watch for confusion, restlessness, hallucinations (seeing things that are not there), or unusual agitation — report to the doctor immediately.
Make sure the patient is in a cool environment — this medicine stops sweating and the patient can overheat, especially in Indian summer weather.
Check that the patient has passed urine within 6–8 hours of receiving the injection — tell the nurse or doctor if not.
Keep the patch, tablets, and used patches away from children and pets — even a used patch contains enough medicine to be dangerous to a small child if sucked or swallowed.
If the patient is wearing a patch, do not touch it with bare hands and then touch your own or anyone else’s eyes."

India-specific adherence support:

Concern	Guidance
Cost-driven non-adherence	“For motion sickness, this medicine is usually needed only occasionally and is affordable. If cost is a concern for regular use (drooling/palliative care), ask your doctor about glycopyrrolate tablets, which are more widely available and often more affordable in India.”
Temperature-sensitive storage	“This medicine does not need a fridge. But keep it below 30°C — in Indian summers, keep medicines in an earthen pot (matka), in an air-conditioned room, or in the coolest cupboard in the house. Do not keep medicines in the car dashboard or glove box.”
Rural access	“If you cannot find this medicine at your local pharmacy (especially the tablet or patch form), tell your doctor — there are alternative medicines that work similarly and are more easily available.”
Polypharmacy burden	“If you are taking many medicines, ask your doctor to check whether all of them are still needed. Some medicines have similar effects and taking too many together can cause side effects.”

BRANDS AVAILABLE IN INDIA

Jan Aushadhi / PMBJP brands:

No Jan Aushadhi brand of hyoscine hydrobromide (injection, tablet, or patch) is currently listed in the PMBJP product catalogue. The drug is not part of the Jan Aushadhi scheme as of the reference date.

Private / Commercial brands — Injection:

Brand Name	Manufacturer	Strength	Availability
Hyoscine Injection (generic)	Various Indian manufacturers	0.4 mg/mL, 1 mL ampoule	Widely available — stocked in most government and private hospital pharmacies. This is the most readily available formulation in India.
Buscopan injection (this is hyoscine BUTYLBROMIDE — NOT hydrobromide)	Sanofi India	20 mg/mL	⚠️ Listed here ONLY to prevent confusion. Buscopan contains hyoscine butylbromide, a DIFFERENT drug. Do NOT substitute for hyoscine hydrobromide.

ℹ️ Important note on branding: In India, hyoscine hydrobromide injection is often supplied under the generic name (“Hyoscine Hydrobromide Injection IP” or “Scopolamine Hydrobromide Injection”) without a prominent brand name, particularly in government hospital supply. Major branded products are less common compared to generic supply. Prescribers should verify the salt form (hydrobromide vs butylbromide) on the ampoule label before administration.

Private / Commercial brands — Oral Tablet:

Brand Name	Manufacturer	Strength	Availability
Kwells	Bayer (imported)	0.3 mg tablet	Limited availability — primarily available through online pharmacies or in select metro city pharmacies (Mumbai, Delhi, Bengaluru). Often imported. Not consistently stocked.

ℹ️ No widely available Indian-manufactured oral tablet of hyoscine hydrobromide could be confirmed at the time of this monograph. Prescribers should verify current availability before prescribing.

Private / Commercial brands — Transdermal Patch:

Brand Name	Manufacturer	Strength	Availability
Transderm Scōp	Baxter / Novartis (imported)	1.5 mg patch (delivers ~1 mg over 72 hours)	Very limited availability in India. Primarily available through specialty pharmacies, imported product channels, or hospital formularies at select tertiary centres in major metros. Not reliably available in most Indian pharmacies.

ℹ️ Domestically manufactured transdermal scopolamine patches are not currently available in India (to the best of available information). Patients requiring the transdermal formulation may need to source it through importation or specialty pharmacy channels.

Private / Commercial brands — Eye Drops:

Limited or no confirmed Indian-manufactured brand of hyoscine hydrobromide 0.25% eye drops is currently marketed. Atropine eye drops (1%) and cyclopentolate eye drops (1%) are widely available from multiple Indian manufacturers and are preferred in clinical practice.

⚠️ CDSCO NSQ / Recall Alerts: No specific Not of Standard Quality (NSQ) alerts or product recalls for hyoscine hydrobromide products were identified at the time of this monograph. Prescribers should verify against the latest CDSCO notifications at https://cdsco.gov.in.

PRICE RANGE (INR)

Prices as of June 2025. Verify current prices on NPPA/1mg/PharmEasy/Jan Aushadhi price lists as prices may change.

Formulation	Strength	Approximate Price Range (INR)	Notes
Injection (ampoule) — generic	0.4 mg/mL, 1 mL ampoule	₹8–25 per ampoule (government supply: ₹5–10; private retail: ₹15–25)	This is the most affordable and most available formulation. Widely used in government hospitals.
Injection (ampoule) — generic	0.6 mg/mL, 1 mL ampoule	₹10–30 per ampoule	Less commonly available than the 0.4 mg/mL strength.
Oral tablet (Kwells or imported generic)	0.3 mg	₹150–400 per strip (varies with import source and availability)	Significantly more expensive due to limited Indian manufacture and import costs. Not a cost-effective option for most Indian patients.
Transdermal patch (Transderm Scōp or equivalent)	1.5 mg patch	₹250–600 per patch (imported)	Very expensive relative to alternatives. Not NPPA price-controlled. Limited availability makes pricing inconsistent.
Eye drops (if available)	0.25%	Data limited — product not consistently marketed in India	—

NPPA Price Control: Hyoscine hydrobromide is NOT currently on the NPPA price-controlled list under the Drug Prices Control Order (DPCO) / NLEM scheduling.

PMBJP (Jan Aushadhi) availability: Not available through Jan Aushadhi stores.

Per-Course Cost Estimates (Typical Use Scenarios):

Scenario	Estimated Cost
Single premedication dose (0.4 mg IM)	₹8–25 (one ampoule) — very affordable
Motion sickness prophylaxis — 1-day trip (oral tablet × 2–3 doses)	₹30–120 (if tablets available)
Motion sickness prophylaxis — 3-day trip (1 transdermal patch)	₹250–600 (if patch available)
Palliative care — terminal secretions (SC, 7 days of continuous use at 1.2 mg/day)	₹25–75 (3 ampoules/day × 7 days = ~21 ampoules) — affordable

ℹ️ Cost comparison note: For motion sickness prophylaxis, the injectable route is the cheapest formulation but impractical for outpatient self-use. Alternative oral antiemetics are significantly more affordable and available: promethazine 25 mg tablets (₹1–3 per tablet), cinnarizine 25 mg tablets (₹1–2 per tablet), meclizine 25 mg tablets (₹2–5 per tablet). Cost-conscious prescribing for motion sickness in India should factor in the limited availability and high cost of hyoscine hydrobromide oral/transdermal formulations.

CLINICAL PEARLS

💡 1. Do NOT confuse hyoscine hydrobromide with hyoscine butylbromide (Buscopan). These are pharmacologically different drugs. Hyoscine hydrobromide crosses the blood-brain barrier → antiemetic, sedative, amnestic. Hyoscine butylbromide does NOT cross the BBB → peripheral antispasmodic only. Prescribing errors between the two are documented, and the consequences include unexpected CNS depression (if hydrobromide is given when butylbromide was intended) or inadequate antiemetic/sedative effect (if butylbromide is given when hydrobromide was intended). Always verify the salt form on the ampoule label. [Evidence-based]

💡 2. For premedication in elderly patients: glycopyrrolate, not hyoscine. Glycopyrrolate (0.1–0.2 mg IV/IM) is the antisialagogue of choice in patients ≥60 years because it does not cross the BBB — no delirium, no cognitive impairment, no postoperative confusion. Hyoscine hydrobromide is a Beers Criteria drug to avoid in older adults. Reserve hyoscine for the rare situation where central sedation/amnesia is specifically desired — and even then, prefer midazolam for amnesia in the elderly. [Evidence-based — Beers Criteria 2023, STOPP criteria v2]

💡 3. Transdermal patch — apply the night BEFORE travel, not the morning of. The patch takes 4–8 hours for initial onset and approximately 24 hours for full steady-state effect. Applying it just before departure provides suboptimal protection for the first several hours of travel. For best results, apply the evening before the journey. [Evidence-based — transdermal PK data]

💡 4. Myth vs Fact — “Hyoscine injection dilates the cervix and speeds up labour.”
Myth: Hyoscine hydrobromide injection (0.4 mg IV/IM) is still used in some Indian labour rooms to “relax the cervix” and accelerate cervical dilation.
Fact: High-quality evidence supporting this practice is lacking. A Cochrane review and multiple Indian studies (including studies from Indian medical colleges) have yielded conflicting results, with most showing no significant reduction in total labour duration. The drug can cause fetal tachycardia, reduced CTG variability (mimicking fetal distress), maternal drowsiness, and neonatal depression. The FOGSI (Federation of Obstetric and Gynaecological Societies of India) does not endorse routine use of hyoscine hydrobromide for labour augmentation. Safer, evidence-based methods of labour management (oxytocin augmentation, epidural analgesia, amniotomy where indicated) should be used. [Evidence-based — Cochrane review; Practice-based — common misconception in Indian practice]

💡 5. In palliative care death rattle: start the antisecretory agent EARLY — at the first sign of audible secretions. Antisecretory drugs (hyoscine hydrobromide, glycopyrrolate) reduce NEW secretion production but do NOT clear already-pooled secretions. Starting late, when large volumes have already accumulated, results in disappointing efficacy. Early intervention provides the best symptom control and reduces family distress. Gentle repositioning (lateral position with head slightly elevated) aids gravitational drainage of existing secretions. [Practice-based — palliative care expert consensus; IAPC guidelines]

💡 6. Anticholinergic burden adds up — count before you prescribe. Before adding hyoscine hydrobromide (ACB score 3), check the patient’s existing medication list. In Indian practice, amitriptyline (for pain or depression), chlorpheniramine (for allergy — often self-medicated OTC), dicyclomine (for IBS), and hydroxyzine (for anxiety/pruritus) are among the most commonly encountered high-ACB drugs. A patient on amitriptyline 25 mg (ACB 3) who then receives hyoscine 0.4 mg (ACB 3) for premedication has a cumulative ACB of 6 — placing them at very high risk of postoperative delirium, especially if elderly. [Evidence-based — ACB scale; Practice-based — Indian prescribing patterns]

VERSION

RxIndia v0.1 — 13 Mar 2026

REFERENCES

The following sources were used to compile this monograph. All text is originally written; no text was copied from any proprietary database.

CDSCO Product Insert — Hyoscine Hydrobromide Injection IP (generic manufacturers; multiple product inserts reviewed). Approved indications, contraindications, dosing, and adverse effects for the Indian market. Specific manufacturer revision dates vary; most recent reviewed inserts from 2022–2024.
Indian Pharmacopoeia 2022 (IP 2022), Indian Pharmacopoeia Commission, Ghaziabad. Monograph on Hyoscine Hydrobromide — specifications, identification, and official standards. 8th Edition.
National List of Essential Medicines (NLEM) India 2022, Ministry of Health & Family Welfare, Government of India. Hyoscine hydrobromide is NOT listed; atropine sulphate and glycopyrrolate are listed as anticholinergic premedications. Ondansetron and dexamethasone are listed antiemetics.
Goodman & Gilman’s The Pharmacological Basis of Therapeutics, 14th Edition (2023). Chapter 9: Muscarinic Receptor Agonists and Antagonists. Pharmacology of scopolamine (hyoscine) — mechanism of action, pharmacokinetics, clinical pharmacology, adverse effects, and drug interactions. Used for pharmacological depth; deferred to CDSCO product inserts for Indian-specific labelling and approved indications.
Harrison’s Principles of Internal Medicine, 21st Edition (2022). Relevant sections on motion sickness, nausea and vomiting, and anticholinergic poisoning.
API Textbook of Medicine, 11th Edition (2019), Association of Physicians of India. Sections on motion sickness, palliative care, and anticholinergic pharmacology. References hyoscine hydrobromide as the drug of choice for motion sickness prophylaxis.
Indian Association of Palliative Care (IAPC) Treatment Guidelines — Symptom management in terminal illness: management of death rattle, malignant bowel obstruction, nausea and vomiting in palliative care. Hyoscine hydrobromide listed as a first-line option for terminal respiratory secretions.
IAP Textbook of Pediatrics, 6th Edition (2021), Indian Academy of Pediatrics. Sections on preanaesthetic medication in children and paediatric palliative care. Dosing references for paediatric anticholinergic use.
Pallium India Training Modules — Essentials of Palliative Care. Drug formulary section: hyoscine hydrobromide for terminal secretions and malignant bowel obstruction.
Kerala State Palliative Care Policy and Treatment Protocols — References hyoscine hydrobromide for symptom management in terminal illness.
American Geriatrics Society 2023 Updated Beers Criteria for Potentially Inappropriate Medication Use in Older Adults. Lists scopolamine (all formulations) as a drug to avoid in older adults. Used as additional international reference for elderly section.
STOPP/START Criteria version 2 (O’Mahony D, et al. Age and Ageing, 2015; 44: 213–218). Used as additional international reference for elderly section — anticholinergic drug cautions.
Anticholinergic Cognitive Burden (ACB) Scale (Boustani M, Campbell N, Munger S, et al. Aging Health, 2008; 4: 311–320). ACB score assignment and cumulative burden methodology.
Parsons’ Diseases of the Eye, 23rd Edition (2019, Indian edition). Elsevier India. Section on cycloplegic and mydriatic agents. Used for ophthalmic indication context.
Cochrane Database of Systematic Reviews — Relevance to the myth vs fact pearl on hyoscine in labour: Samuels LA, Christie L, Roberts-Gittens B, Fletcher H, Frederick J. “The effect of hyoscine butylbromide on the first stage of labour in term pregnancies.” Cochrane Database Syst Rev, 2007. (Note: Most Cochrane reviews address hyoscine butylbromide in labour, not hydrobromide; the distinction is noted. Indian studies on hyoscine hydrobromide in labour have shown conflicting results — referenced as general evidence for the clinical pearl.)
NPPA (National Pharmaceutical Pricing Authority) — Drug Prices Control Order (DPCO) schedule and ceiling price notifications. Hyoscine hydrobromide is NOT currently price-controlled.
PMBJP (Pradhan Mantri Bhartiya Janaushadhi Pariyojana) — Product catalogue reviewed. No hyoscine hydrobromide product currently listed.
CDSCO website (https://cdsco.gov.in) — Reviewed for banned FDC notifications, NSQ alerts, and product recall notices relevant to hyoscine-containing formulations. No specific alerts identified for hyoscine hydrobromide.
PvPI (Pharmacovigilance Programme of India) — ADR reporting methodology referenced. IPC National Coordinating Centre, Indian Pharmacopoeia Commission.

Non-selective Antimuscarnic - Centrally Acting

Medication Registry

Scopolamine

Explore More

Quick Links